(19) World Intellectual Property Organization International Bureau



L HADI B OMADONI II ORDAN O RANKA KIRAL I 71 ML INGERI DARIYA KAYA BAHITA JURI DITANGA KARA MAN MARA

(43) International Publication Date 7 June 2001 (07.06.2001)

PCT

(10) International Publication Number WO 01/40301 A2

(51) International Patent Classification7:

C07K 14/47

(21) International Application Number: PCT/EPON/11915

(22) International Filing Date: 28 November 2000 (28.11.2000)

(25) Filing Language:

Not Applicable Not ruther lights

English

(26) Publication Language:

English

(30) Priority Data: 99309667.6

1 December 1999 (01.12.1999) E

(71) Applicants (for all designated States except US): AKZO NOBEL N.V. [NL/NL]; Velperweg 76, NL-6824 BM Arnhem (NL). MEDICAL RESEARCH COUNCIL [GB/GB]; 20 Park Crescent, London W1N 4AL (GB). UNIVERSITY OF EDINBURGH [GB/GB]; Old College, South Bridge, Edinburgh, Central Scotland EH8 9YL (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): PORTEOUS, David [GB/GB]; Cherry Trees, 8 Cammo Gardens, Edinburgh, Central Scotland EH4 8EH (GB). MILLAR, Kirsty [GB/GB]; 16 Warrender Park Terrace, Edinburgh, Central Scotland EH9 1EG (GB). BLACKWOOD, Douglas

[GB/GB]; 7 Pitsligo Road, Edinburgh, Central Scotland EH9 1EG (GB).

- (74) Agents: DE WEERD, P. et al.; P.O. Box 20, Wethouder van Eschstraat 1, NL-5340 BH Oss (NL).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

 Without international search report and to be republished upon receipt of that report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

A2

(54) Title: A NOVEL GENE, DISRUPTED IN SCHIZOPHRENIA

(57) Abstract: A newly identified gene, DIS1 is disrupted by a (1;11)(q42.1;q14.3) translocation which segregates with schizophrenia. We have examined the genomic structure of DIS1 and found that the gene consists of 13 exons estimated to extend across at least 300kb of DNA. Exon 11 contains an alternative splice site which removes 66 nucleotides from the open reading frame. The final intron of DIS1 belongs to the rare AT-AC class of introns. 8 expressed sequence tags (ESTs) located within introns 3.7,9 and 10 of DIS1 have also been identified. These ESTs have not yet been assigned to DIS1 and may therefore represent further novel genes in the region.

WO 01/40301

A novel gene, disrupted in schizophrenia

The present invention relates to a newly identified DNA sequence which surrounds a breakpoint on chromosome 1 involved in a balanced t(1;11)(q42.1;q14.3) translocation as well as to a gene disrupted by this translocation event and its encoded proteins as well as to antibodies thereto and their use as a medicament. The invention also relates to methods for the detection of the translocation event as well as to methods for the in vitro diagnosis of a psychiatric disorder. Moreover, the invention also relates to transformed cell lines.

10

20

25

Family, twin and adoption studies have convincingly demonstrated a significant genetic contribution to schizophrenia (1995, Lancet 346: 678-682, and references therein) and have driven studies directed at identification of this genetic component. Schizophrenia is a complex disease and the multifactorial and probable genetic heterogeneity of the condition complicates the application and interpretation of conventional linkage and association studies. At present, however, no specific genes have been described which could play a role in schizophrenia.

Previously, a balanced t(1;11)(q42.1;q14.3) translocation was reported which is linked to schizophrenia and other related mental illness in a large Scottish family (1990, Lancet 336: 13-16) with a maximum LOD of 6.0 (Douglas Blackwood, in preparation). Mapping of the translocation breakpoint on chromosome 11, and the accompanying search for neighbouring genes has already been reported (1997, Am. J. Med. Genet. 74: 82-90, 1998, Pyschiatr. Genet. 8: 175-181). No evidence for the presence of any part of a gene closer than 250kb to the breakpoint has been found.

It will be clear that there is a great need for the elucidation of genes related to schizophrenia in order to unravel the various roles these genes may play in the disease process. A better knowledge of the genes involved in schizophrenia and the mechanism of action of their encoded proteins might help to create a better insight into the etiology of this psychiatric disorder and its underlying molecular mechanisms. This could eventually lead to improved therapy and better diagnostic procedures.

The present invention provides such a novel gene which is located on chromosome 1 and is directly disrupted by the translocation event. More specific, the present invention provides for a gene, tentatively called DIS1 (Disrupted In Schizophrenia) whose cDNA sequence is shown in SEQ ID NO:1. DIS1 is disrupted within an intron of the gene with the result that a proportion of the coding sequence has been translocated to chromosome 11.

The protein encoded by DIS1 is predicted to have a globular N-terminal domain(s) and a helical C-terminal domain with the potential to interact with other proteins via formation of a coiled coil. The coiled-coil structure is present in several proteins (particularly microtubule binding proteins) which are involved in the development and functioning of the nervous system. The putative structure of DIS1 is therefore compatible with a role in the nervous system.

15

DIS1 consists of 13 exons which we estimate to extend across at least 300kb of genomic DNA. The translocation breakpoint lies within intron 8 of this gene. The effect of the translocation is therefore to remove exons 9-13 to chromosome 11. There is a commonly used alternative splice site, which does not disrupt the open reading frame, within exon 11 which give rise to two distinct polypeptides as provided in SEQ ID NO: 2 and SEQ ID NO: 3. Table 1 shows the nucleotide sequences of the splice sites. The sequence of intron 8 is now revealed I SEQ ID NO: 4. At nucleotide 8432 a gap of unknown size occurs in the sequence.

The density of genes in the chromosome 1 breakpoint region is apparently high since, in addition to DIS1, 8 independent ESTs have also been identified. While this may suggest the presence of other genes in the region, it is also possible that some of these ESTs represent differentially spliced exons of DIS1.

Table 1 DIS1 splice site sequences

exon	exon size	position	splice acceptor	splice donor
1	120bp	1-120	N/A	CACCGCGCAGgtagggagc
2	980bp	121-1100	ttcttcccagGCAGCCGGGA	GCAGATGGAGgtcagtgtct
3	70bp	1101-1170	accaacatagGTAATATCCT	TATGATAAAGgtgagtttta
4	151bp	1171-1321	gggtttccagCTGAGACGTT	CCACTCAGCAgtgaatacct
5	130bp	1322-1451	ttgttttaagGGCCAGCGGA	GCAGCTACAGgtgagcaggt
6	236bp	1452-1687	ttctctacagAAAGAAATTG	CCATAAGGAGgtactgctga 1
7	55bp	1688-1742	attcttccagCCTCCAGGAA	CACTACTAAGgtaagtacct
8	103bp	1743-1845	ctcccctagGTGTGTATGA	GCCATATCAGgtaactggca 1
9	189bp	1846-2034	cgtgctgtagGAAACCATTT	ACTGCCTATGgtaggtagtg
10	61bp	2035-2095	ttttccccagAAACAAGTGT	AACTGTGCAGgtaaggataa 1
11a	199bp	2096-2294	tctgtctcagCTGCAAGTGT	CCCTTTGAAGgtattggaag
11b	265bp	2096-2360	tctgtctcagCTGCAAGTGT	ACAGAAAGAGgtctgtcctt
12	118bp	2361-2478	ctctcgccagGAATCTTACA	GATCTCATTCatatcctttt 1
13	4430-4585*	2479-6913	ctccttaacaatgtgcccacAGTCTCTCAG	N/A

Exon size depends upon poly(A) signal usage and poly(A) addition site selection

DIS1 is predicted to encode a protein with an N-terminal globular head consisting mainly of beta-sheet, and solvent-exposed helical tail with the potential to form coiled-coils. The transition from beta-sheet to alpha-helix occurs essentially at the boundary between exons 2 and 3. Exons 1 and 2 therefore encode the putative globular domain(s), while exons 3 to 13 encode the putative helical tail of DIS1.

We propose that DIS1 should be considered as candidate gene involved in the aetiology of psychiatric disorders because it is directly disrupted by the translocation. In support of this contention is the predicted structure of DIS1, which is compatible with a role in development and functioning of the nervous system. The information contained herein, now enables the skilled person to assess the gene as candidate in psychotic individuals unrelated to members of the family carrying the translocation. This is particularly important given that our mapping of the chromosome 1 breakpoint region has identified several ESTs which indicates the possible presence of additional genes. Even if such genes are not directly disrupted by the translocation, positional effects on their expression cannot be ruled out. Determination of the genomic structure of DIS1 has provided the information required to look for mutations

in all of the transcribed sequence plus splice sites and DIS1 can now be evaluated by means of mutation screening and association studies.

The sequences of the present invention can be used to derive primers and probes for use in DNA amplification reactions in order to perform diagnostic procedures or to identify further, neighbouring genes which also may contribute to the development of schizophrenia.

It is known in the art that genes may vary within and among species with respect to their nucleotide sequence. The DIS1 genes from other species may be readily identified using the above probes and primers. Therefore, the invention also comprises functional equivalents, which are characterised in that they are capable of hybridising to at least part of the DIS1 sequence shown in SEQ ID NO: 1, preferably under high stringency conditions.

15

Two nucleic acid fragments are considered to have hybridisable sequences if they are capable to hybridising to one another under typical hybridisation and wash conditions, as described, for example in Maniatis, et al., pages 320-328, and 382-389, or using reduced stringency wash conditions that allow at most about 25-30% basepair mismatches, for example: 2x SSC, 0.1% SDS, room temperature twice, 30 minutes each, then 2x SSC, 0.1% SDS 37 °C once, 30 minutes; then 2X SSC, room temperature twice ten minutes each. Preferably, homologous nucleic acid strands contain 15-25% basepair mismatches, even more preferably 5-15% basepair mismatches. These degrees of homology can be selected by using wash conditions of appropriate stringency for identification of clones from gene libraries or other sources of genetic material, as is well known in the art.

Furthermore, to accommodate codon variability, the invention also includes sequences coding for the same amino acid sequences as the sequences disclosed herein. Also portions of the coding sequences coding for individual domains of the expressed protein are part of the invention as well as allelic and species variations thereof. Sometimes, a gene expresses different isoforms in a certain tissue which

includes splicing variants, that may result in an altered 5' or 3' mRNA or in the inclusion of an additional exon sequence. Alternatively, the messenger might have an exon less as compared to its counterpart as exemplified in the sequences enlisted here (SEQ ID NO: 3 contains an additional 22 amino acids as compared to SEQ ID NO 2 due to an alternative splicing event). These sequences as well as the proteins encoded by these sequences all are expected to perform the same or similar functions and form also part of the invention.

The sequence information as provided herein should not be so narrowly construed as to require inclusion of erroneously identified bases. The specific sequence disclosed herein can be readily used to isolate further genes which in turn can easily be subjected to further sequence analyses thereby identifying sequencing errors. Thus, in one aspect, the present invention provides for isolated polynucleotides encoding a novel gene, disrupted in schizophrenia.

15

The DNA according to the invention may be obtained from cDNA. Alternatively, the coding sequence might be genomic DNA, or prepared using DNA synthesis techniques. The polynucleotide may also be in the form of RNA. The polynucleotide may be in single stranded or double stranded form. The single strand might be the coding strand or the non-coding (anti-sense) strand.

The present invention further relates to polynucleotides which have at least 80%, preferably 90% and more preferably 95% and even more preferably at least 98% identity with SEQ ID NO:1. Such polynucleotides encode polypeptides which retain the same biological function or activity as the natural, mature protein.

The percentage of identity between two sequences can be determined with programs such as DNAMAN (Lynnon Biosoft, version 3.2). Using this program two sequences can be aligned using the optimal alignment algorithm of Smith and Waterman (1981, J. Mol. Biol, 147:195-197). After alignment of the two sequences the percentage identity can be calculated by dividing the number of identical nucleotides between the two sequences by the length of the aligned sequences minus the length of all gaps.

The DNA according to the invention will be very useful for *in vivo* or *in vitro* expression of the novel gene according to the invention in sufficient quantities and in substantially pure form.

5

In another aspect of the invention, there are provided polypeptides comprising the amino acid sequence encoded by the above described DNA molecules.

Preferably, the polypeptides according to the invention comprise at least part of the amino acid sequences as shown in SEQ ID NO:2 and SEQ ID NO:3.

Also functional equivalents, that is polypeptides homologous to SEQ ID NO: 2 or SEQ ID NO: 3 or parts thereof having variations of the sequence while still maintaining functional characteristics, are included in the invention.

15

The variations that can occur in a sequence may be demonstrated by (an) amino acid difference(s) in the overall sequence or by deletions, substitutions, insertions, inversions or additions of (an) amino acid(s) in said sequence. Amino acid substitutions that are expected not to essentially alter biological and immunological activities, have been described. Amino acid replacements between related amino acids or replacements which have occurred frequently in evolution are, inter alia Ser/Ala, Ser/Gly, Asp/Gly, Asp/Asn, Ile/Val (see Dayhof, M.D., Atlas of protein sequence and structure, Nat. Biomed. Res. Found., Washington D.C., 1978, vol. 5, suppl. 3). Based on this information Lipman and Pearson developed a method for rapid and sensitive protein comparison (Science, 1985, 227, 1435-1441) and determining the functional similarity between homologous polypeptides. It will be clear that also polynucleotides coding for such variants are part of the invention.

The polypeptides according to the present invention include the polypeptides comprising SEQ ID NO:2 and SEQ ID NO:3 but also their isoforms, i.e. polypeptides with a similarity of 70%, preferably 90%, more preferably 95%. Also portions of such polypeptides still capable of conferring biological effects are included. Especially

portions which still bind to ligands form part of the invention. Such portions may be functional per se, e.g. in solubilized form or they might be linked to other polypeptides, either by known biotechnological ways or by chemical synthesis, to obtain chimeric proteins. Such proteins might be useful as therapeutic agent in that they may substitute the gene product in individuals with abberant expression of the DIS1 gene.

The sequence of the gene may also be used in the preparation of vector molecules for the expression of the encoded protein in suitable host cells. A wide variety of host cell and cloning vehicle combinations may be usefully employed in cloning the nucleic acid sequence coding for the DIS1 gene of the invention or parts thereof. For example, useful cloning vehicles may include chromosomal, non-chromosomal and synthetic DNA sequences such as various known bacterial plasmids and wider host range plasmids and vectors derived from combinations of plasmids and phage or virus DNA.

Vehicles for use in expression of the genes or a ligand-binding domain thereof of the present invention will further comprise control sequences operably linked to the nucleic acid sequence coding for a ligand-binding domain. Such control sequences generally comprise a promoter sequence and sequences which regulate and/or enhance expression levels. Of course control and other sequences can vary depending on the host cell selected.

Suitable expression vectors are for example bacterial or yeast plasmids, wide host range plasmids and vectors derived from combinations of plasmid and phage or virus DNA. Vectors derived from chromosomal DNA are also included. Furthermore an origin of replication and/or a dominant selection marker can be present in the vector according to the invention. The vectors according to the invention are suitable for transforming a host cell.

Recombinant expression vectors comprising the DNA of the invention as well as cells transformed with said DNA or said expression vector also form part of the present invention.

Suitable host cells according to the invention are bacterial host cells, yeast and other fungi, plant or animal host such as Chinese Hamster Ovary cells or monkey cells. Thus, a host cell which comprises the DNA or expression vector according to the invention is also within the scope of the invention. The engineered host cells can be cultured in conventional nutrient media which can be modified e.g. for appropriate selection, amplification or induction of transcription. The culture conditions such as temperature, pH, nutrients etc. are well known to those ordinary skilled in the art.

The techniques for the preparation of the DNA or the vector according to the invention as well as the transformation or transfection of a host cell with said DNA or vector are standard and well known in the art, see for instance Sambrook et al., *Molecular Cloning: A laboratory Manual.* 2nd Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1989.

The proteins according to the invention can be recovered and purified from recombinant cell cultures by common biochemical purification methods including ammonium sulfate precipitation, extraction, chromatography such as hydrophobic interaction chromatography, cation or anion exchange chromatography or affinity chromatography and high performance liquid chromatography. If necessary, also protein refolding steps can be included.

25

30

DIS1 gene products according to the present invention can be used for the *in vivo* or *in vitro* identification of novel ligands or analogs thereof. For this purpose binding studies can be performed with cells transformed with DNA according to the invention or an expression vector comprising DNA according to the invention, said cells expressing the DIS1 gene products according to the invention.

Alternatively also the DIS1 gene products according to the invention as well as ligand-binding domains thereof can be used in an assay for the identification of functional ligands or analogs for the DIS1 gene products.

- Methods to determine binding to expressed gene products as well as *in vitro* and *in vivo* assays to determine biological activity of gene products are well known. In general, expressed gene product is contacted with the compound to be tested and binding, stimulation or inhibition of a functional response is measured.
- Thus, the present invention provides for a method for identifying ligands for DIS1 gene products, said method comprising the steps of:
 - a) introducing into a suitable host cell a polynucleotide according to the invention,
 - b) culturing cells under conditions to allow expression of the DNA sequence
 - c) optionally isolating the expression product

15

- d) bringing the expression product (or the host cell from step b)) into contact with potential ligands which will possibly bind to the protein encoded by said DNA from step a);
- e) establishing whether a ligand has bound to the expressed protein.
- 20 f) Optionally isolating and identifying the ligand

As a preferred way of detecting the binding of the ligand to the expressed protein, also signal transduction capacity may be measured.

- The present invention thus provides for a quick and economic method to screen for therapeutic agents for the prevention and/or treatment of diseases related to schizophrenia. The method is especially suited to be used for the high throughput screening of numerous potential compounds.
- 30 Compounds which activate or inhibit the function of DIS1 gene products may be employed in therapeutic treatments to activate or inhibit the polypeptides of the present invention.

Also within the scope of the invention are antibodies, especially monoclonal antibodies raised against the polypeptide molecule according to the invention. Such antibodies can be used therapeutically to inhibit DIS1 gene product function and diagnostically to detect DIS1 gene products.

The invention furthermore relates to the use of the DIS1 gene products as part of a diagnostic assay for detecting psychiatric abnormalities or susceptibility to psychiatric disorders related to mutations in the nucleic acid sequences encoding the DIS1 gene. Such mutations may e.g. be detected by using PCR (Saiki et al., 1986, Nature, 324, 163-166). Also the relative levels of RNA can be determined using e.g. hybridization or quantitative PCR technology. The presence and the levels of the DIS1 gene products themselves can be assayed by immunological technologies such as radioimmuno assays, Western blots and ELISA using specific antibodies raised against the gene products. Such techniques for measuring RNA and protein levels are well known to the skilled artisan.

The determination of expression levels of the DIS1 gene products in individual patients may lead to fine tuning of treatment protocols.

20

Also, transgenic animals may be prepared in which the expression of the DIS1 gene is altered or abolished.

Legends to the figures

25

Figure 1 Alignment of sequence immediately flanking the breakpoints from the normal chromosome 1, der (1), der (11) and normal chromosome 11 (wt1, der (1), der (11) and wt11 respectively).

Figure 2 Map of the chromosome 1 breakpoint region containing *DIS1*. Black boxes, *DIS1* exons; Letters marking vertical arrows, position of ESTs. Positions of the putative CpG island, putative translation start and stop sites, polyadenylation signals

and alternative splice site are indicated. EST accession numbers: A=AA777274, B=AA361879, C=AA311762, D=Hs.96883, E=AA249072, F=W04811, G=D78808, H=N49833, I=W29023/AA093172, J&K=H71071/Z40262, M=AA610789, 13=Hs.26985. ESTs J and K are located extremely close together such that their order could not be determined.

Examples

10 Example 1

Cloning of the Chromosome 1 Translocation Breakpoint

We have previously described the isolation of a 2.5kb EcoRI fragment (wt11) containing the normal chromosome 11 translocation breakpoint, and demonstrated that it hybridises to EcoRI fragments of 2.7kb and 7kb from the der (1) and der (11) 15 chromosomes respectively (1998, Psychiatr. Genet. 8: 175-181). This chromosome 11 breakpoint fragment was subcloned, and used to prepare a 2.15kb HindIII/EcoRI repeat-free sub-fragment with which an EcoRI total digest genomic library made from a cell line from a translocation carrier (MAFLI, 1993, Am. J. Hum. Genet. 52: 478-490) was screened. A 2.7kb EcoRI fragment, presumed to correspond to the der (1) 20 translocation fragment was obtained. This was confirmed by its hybridisation pattern (figure 1), where it hybridises to a 2.7kb fragment from MIS7.4, a hybrid cell line carrying the der (1) chromosome as its human component (1998, Psychiatr. Genet. 8: 175-181). Three fragments are visible from MAFLI; the 2.5kb wild-type 11 breakpoint fragment; the 2.7kb der (1) fragment and a fragment of 7.3kb, assumed to be the wild-type chromosome 1 breakpoint fragment. This was confirmed using normal control human DNA which also shows hybridisation of the probe to the 2.5kb chromosome 11 breakpoint fragment, and to a 7.3kb fragment which must therefore be from chromosome 1.

The 2.7kb der (1) fragment was used to rescreen the library, avoiding any clones which had previously hybridised to the chromosome 11 breakpoint fragment, and this yielded a 7.3kb clone (wt1), corresponding to the chromosome 1 breakpoint fragment.

Example 2

Identification of the Breakpoint

The cloned wt11, wt1 and der (1) fragments were sequenced and the positions of the translocation breakpoints were identified by comparisons between these three sequences. Primers designed from wt11 and wt1 sequence amplified a 1.4kb fragment containing the breakpoint from the der (11) chromosome by PCR, and the product was partially sequenced. An alignment of the breakpoint sequences from each of the four chromosomes is presented in figure 1. This shows that the translocation event resulted in no rearrangement at all on the der (1) chromosome, and a small rearrangement on the der (11), where there has been a deletion of the nucleotides TCAG accompanied by insertion of AA. This breakpoint sequence and minor rearrangement has been confirmed by genomic sequence analysis of two other translocation carriers (data not shown). The position of the breakpoint has also been confirmed using pairs of primers, one primer pair from each side of the breakpoint, for PCR on genomic DNA from MIS7.4 and MIS39, cell lines carrying the der(1) and der (11) chromosomes respectively (data not shown).

Example 3

20 Breakpoint Sequence Analysis

The sequences of the breakpoint fragments from chromosomes 1 and 11 were used to search sequence databases using BLAST (1997, Nucleic. Acids. Res. 25: 3389-3402) to identify matches indicating the presence of a gene, and also analysed using the suite of gene recognition and analysis programmes encompassed by Nucleotide ldentify X (NIX, http://menu.hgmp.mrc.ac.uk/menu-bin/Nix/Nix.pl).

BLAST searches of sequence databases identified sequence from one end of a BAC clone (Genbank/EMBL accession number AQ105798) within the wt11 fragment, but nothing else of note. Neither did NIX convincingly predict any exons to be present within the chromosome 11 breakpoint sequence. However the wt1 fragment contains several interesting sequences. There is a tandemly repeated TAA trinucleotide which is contained within three overlapping sequence tagged sites (Genbank/EMBL accession numbers G09671, G09453 and G07779). These correspond to the marker

D1S1621, which maps approximately 120bp below the breakpoint. There are also sequence matches to the ends of three different BAC clones (Genbank/EMBL accession numbers AQ112950, AQ078498 and B40542).

From Genbank and EMBL, sequence matches to three separate expressed sequence tags (ESTs), and a messenger RNA, are also contained within the wt1 fragment, all distal to the breakpoint. These are AA249072 (which overlaps with *D1S1621*), W04811, D78808 and AB007926, mapping approximately 80bp, 1.8kb, 2.8kb and 3.7kb from the breakpoint respectively (figure 2).

Homology to AA249072 and W04811 extends across the whole sequence obtained 10 from each cDNA. However sequence corresponding to wt1 in D78808 could be spurious. Only 103 nucleotides of the total 350 in the EST sequence are contained within the wt1 sequence, yet this short match does not apparently correspond to an exon since there are no flanking splice sites. The remaining sequence is homologous other **ESTs** (UniGene to several cluster Hs.31446, http://www.ncbi.nlm.nih.gov/UniGene/index.html), none of which contain any wt1 sequence or are even present on chromosome 1, as judged by a lack of hybridisation to genomic DNA from the chromosome 1 human/mouse hybrid cell line A9(Neo-1)-4 (data not shown). AB007926 consists of 6833 nucleotides of a brain-expressed transcript from chromosome 1 (1997, DNA Res. 4: 345-349). Only 189 nucleotides of this transcript are coincident with wt1.

NIX identified one putative exon with consensus splice sites on the forward strand of wt1. This exon contains all of the sequence match to mRNA AB007926. The match ends at the predicted splice sites, demonstrating the accuracy of the prediction.

25 Example 4

Contia Construction

Genomic clones from the region were isolated from a PAC library, RPCI1 (1996, Construction of bacterial artificial chromosome libraries using the modified P1 (PAC) System. *In* "Current Protocols in Human Genetics", N. C. Dracopoli, J. L. Haines, B. R. Korf, D. T. Moir, C. C. Morton, C. E. Seidman, J. G. Seidman and D. R. Smith, Eds., Unit 5.15 Pub. John Wiley and Sons, New York) distributed by the United Kingdom Human Genome Mapping Project Resource Centre, and a chromosome 1

cosmid library, provided by the Resource Centre of the German Human Genome Project at the Max-Planck-Institute for Molecular Genetics (1994, Nature, 367: 489-491, 1999, Nature Genetics, 22: 22). Contig construction essentially required three phases. Initially, genomic clones were identified by screening libraries with sequence 5 flanking the breakpoint, microdissection clone MD258 (1995, Cytogenet. Cell Genet. 70; 35-40), or with several cDNA fragments from DIS1. Overlaps between the clones were then determined by end sequencing using oligonucleotides bordering the cosmid and PAC vector cloning sites (data not shown). Pairs of primers were designed from the resulting sequence and overlapping clones were identified by PCR (data not shown). For verification, the PCR products were hybridised to Southern blots of digested PAC and cosmid DNA (data not shown). Finally, remaining gaps in the contig were filled by further rounds of library screening using PCR products generated from clone ends. In addition, cosmid ICRFc112B0519Q6 was used to screen the PAC library to extend the contig in the proximal direction. Two markers, 15 D1S251 and D1S1621, have been mapped on this contig. D1S251 was mapped by PCR, while the location of D1S1621 immediately distal to the breakpoint was determined by genomic sequencing. The locations of DIS1 exons 1-3 and 5-13 and of all the ESTs with respect to the cosmids and PACs were determined by hybridisation of oligonucleotides (not shown) to digested cosmid and PAC DNA. 20 ESTs 10 and 11 are located extremely close together such that their order with respect to the contig could not be determined by hybridisation. DIS1 exon 4 is known to be present in cosmid ICRFc112D2299QD4, but was not otherwise mapped because of the apparent presence of numerous related sequences in the surrounding DNA.

25

Example 5

A Contig Spanning the Chromosome 1 Translocation Breakpoint

To investigate the genomic structure of DIS1 we first constructed a contiguous clone map spanning the chromosome 1 breakpoint (Fig. 1). This contig is estimated to extend across at least 400kb based on average PAC and cosmid sizes of 130kb and 35kb respectively. Cosmid fluorescence *in situ* hybridisation to the translocation cell line MAFLI was employed to confirm the orientation of the contig, and that it crosses

the translocation breakpoint. Cosmids spanning the breakpoint, and located distal and proximal were found to hybridise as predicted. Cosmid ICRFc112I0142Q6 hybridises to the normal chromosome 1, and the derived 1 and derived 11 chromosomes, indicating that it crosses the breakpoint. Hybridisation of cosmid ICRFc112D1274QD4 to the normal chromosome 1 and derived 1, shows that it is located proximal to the breakpoint. Finally, signal from cosmid ICRFc112G1395QD4 is visible on the normal chromosome 1 and the derived chromosome 11 demonstrating that this cosmid lies distal to the breakpoint.

10 Example 6

Genomic Structure of DIS1

Direct cosmid sequencing using primers designed from DIS1 cDNA sequence was used to determine the intron/exon structure of DIS1. Resulting genomic sequence was aligned with cDNA sequence and splice sites identified at the points of divergence (table 1). Exons 1-3 and 5-13 were identified by this method. For technical reasons, exon 4 proved more difficult and splice site sequences were eventually identified by subcloning a genomic fragment containing the exon from a cosmid, followed by sequencing.

DIS1 consists of 13 exons extending across at least 300kb of genomic DNA (Fig. 1).

A region of 66 nucleotides which is deleted from some DIS1 transcripts was found to arise from utilisation of an internal splice donor site within exon 11 and the normal splice acceptor site of the same exon. The final intron of DIS1 is a member of the extremely rare AT-AC class of introns (1997, Trends. Biochem. Sci. 22:132-137). This intron has the consensus 5' and 3' splice site sequences, atatectt and yccac respectively, as well as the consensus branch-site element, teettaac, close to the 3' splice site as shown in table 1. All the other introns are of the common class I type.

Example 7

Mapping of Additional Transcribed Sequences in the Region

During contig construction, all of the sequences generated from the ends of the PACs and cosmids, miscellaneous sequences and the sequence of ICRFc112I0142Q6, were used to screen Genbank and EMBL in search of

homologies to expressed sequence tags (ESTs). The locations of the 8 ESTs identified by database screening are shown (Fig. 1). Unigene cluster Hs.26985 (13) is derived from the 3' UTR of DIS1, while the remaining 8 ESTs have not yet been assigned to any known gene.

5

Example 8

Expression of DIS1

When hybridised to Northern blots, DIS1 was found to be present in all adult human tissues examined, as a transcript of approximately 8.1kb. Various smaller transcripts hybridise to the same probe. Although these may represent DIS1 splice variants, their significance is not yet known. In agreement with the Northern blot data, RT-PCR using primers towards the 5' end of DIS1 on a range of human foetal tissues also detected transcripts in every tissue tested (table 2).

Sample	age	DIS1	DIS1
	(weeks)	proximal	distal
brain	8.3	+	+ (2)
	10.3	+	+ (2)
	13.3	+	+ (2)
heart	8.0	+	+ (2)
	8.8	+	+ (2)
	9.1	+	+ (2)
	9.3	+	+ (2)
liver	10.6	+	+ (2)
kidney	10.0	+	+ (2)
spleen	14.8	+	+ (2)
limb	10.3	+	+ (2)

Table 2 RT-PCR analysis of DIS1 on a range of human foetal tissues. Approximate ages of gestation are given in weeks. 2: two bands obtained using one primer pair, +: transcript detected.

Example 9

Tissue-specific distribution of DIS1

Analysis of DIS1 expression indicates that the gene is widely expressed in foetal tissues, and that DIS1 transcripts are present in all adult tissues examined. However, as well as normal functioning, it is also necessary to study what effect the translocation may have had on overall expression of the gene. DIS1 is disrupted within the open reading frame which may cause (1) production of a truncated transcript and protein retaining only one of the putative leucine zippers, (2) silencing of the disrupted allele, or (3) production of a fusion transcript/protein from a gene on chromosome 11.

Example 10

Cell Culture

The lymphoblastoid cell line MAFLI from an individual bearing the t(1;11)(q42.1;q14.3) translocation, somatic cell hybrids MIS7.4 and MIS39 bearing the der (1) or der (11) translocation chromosomes respectively, and their culture conditions, have been described previously (1993, Am. J. Hum. Genet. 52: 478-490). Der (1) refers to the derived chromosome 1 where DNA from 1q42.1-qter has been lost and replaced with chromosome 11 material from 11q14.3-qter. Der (11) refers to the reciprocal derived chromosome 11. The cell line A9(Neo-1)-4, a mouse A9 hybrid cell line carrying human chromosome 1, and its culture requirements, have been previously reported (1989, Jpn. J. Cancer Res., 80: 413-418).

Example 11

25 PCR analysis of the breakpoint region of DIS1

A 1.4kb product was amplified from the der 11 chromosome using one primer specific for chromosome 11 proximal to the breakpoint (ggctggatattgcccttgagccataatt) and one primer specific for chromosome 1 distal to the breakpoint (agaacagaggaggacgatgatgac). This product was obtained using the cell line MIS39 which carries the der 11 chromosome. This product is only obtainable from the translocated chromosome.

Example 12

FISH analysis of the breakpoint region of DIS1

Cosmid fluorescence *in situ* hybridisation to the translocation cell line MAFLI was employed to confirm that the contig crosses the translocation breakpoint. Cosmid 5 ICRFc112l0142Q6 hybridises to the normal chromosome 1, and the derived 1 and derived 11 chromosomes, indicating that it crosses the breakpoint.

Example 13

Methods

10 Fluorescence in situ Hybridisation

Cosmids were mapped in relation to the chromosome 1 breakpoint using 2-7 day old slides of metaphase chromosomes prepared from the translocation cell line MAFLI by conventional methods. Cosmid DNA was labelled with dUTP-biotin by standard nick translation. FISH was carried out essentially as previously described (1995, Genomics 28: 420-428). Slides were examined on a Leitz microscope and suitable metaphases scanned with a BioRad MRC-600 confocal laser scanning system.

DNA Preparation

Cosmid and PAC DNA was prepared by standard methods (Sambrook et al., 20 *Molecular Cloning: A laboratory Manual*. 2nd Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1989).

Prior to sequencing, cosmid and PAC DNA was subjected to a phenol/chloroform clean-up step, followed by ethanol precipitation. Alternatively, cosmid DNA was prepared using Qiagen plasmid midi kits, followed by dialysis. Cosmid DNA prepared for sequencing was stored at 4°C. Plasmid DNA was prepared using QIAGEN plasmid midi kits.

DNA Sequencing

sequencing carried Cosmid end was out using 928 primers 30 (aggcgcagaactggtaggtatg) and 929 (gctaaggatggtttctagcgatg). PAC sequencing was carried out using primers SP6 (tactgtttttgcgatctgccgttt) **T7** (aatacgactcactatagggaga). For cosmids and PACs 0.5-1 microgrammes of DNA was sequenced using ABI PRISM Big Dye terminator cycle sequencing ready reaction kits with 60ng of primer. Plasmid DNA sequencing reactions were performed using ABI PRISM dRhodamine terminator cycle sequencing ready reaction kits and the products separated on an ABI 377 DNA sequencer (PE Applied Biosystems), according to the manufacturers instructions. Resulting sequence was analysed using the GCG package of sequence analysis software (Wisconsin package version 9.1, Genetics Computer Group, Madison, Wisc.). BLAST (1997, Nucleic. Acids. Res. 25: 3389-3402) searches were carried out at the National Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov/).

10

RNA Extraction and cDNA Synthesis

Human foetal tissues were obtained from the Medical Research Council Tissue Bank. Total RNA was extracted using RNazol B[™] (Biogenesis Ltd.) according to the manufacturers instructions. First strand cDNA synthesis was carried out on DNAse I treated RNA using the random hexamer primer from the SUPERSCRIPT[™] Preamplification System (GIBCO BRL) according to the manufacturers instructions. 1 microlitre of the resulting cDNA was used in standard PCR reactions.

Subcloning the Chromosome 11 Breakpoint Fragment

The 2.5kb EcoRI fragment isolated as described previously (1998, Psychiatr. Genet. 8: 175-181) was cloned into EcoRI-digested pBluescript SK (-) (Stratagene) using standard methods (Sambrook et al., Molecular Cloning: A laboratory Manual. 2nd Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1989).

25 Genomic Library Construction and Screening

Genomic DNA from the translocation cell line MAFLI was digested with *EcoRI*, ligated into *EcoRI*-digested and dephosphorylated lambda ZAP II (Stratagene), and packaged using Gigapack Gold II packaging extract (Stratagene) according to the manufacturers instructions. Bacteriophage were plated using *E. coli* XL1-Blue MRF' and the library of clones screened using standard methods. Excision of clones from the lambda vector was carried out as advised by the manufacturer, releasing genomic fragments cloned into pBluescript SK (-). The library was screened using

the 2.15kb repeat-free *HindIII/EcoRI* fragment containing the chromosome 11 breakpoint, followed by the 2.7kb der (1) fragment. Of 1x10⁷ clones screened, one copy of the 2.5kb chromosome 11 fragment, four copies of the 2.7kb der (1) fragment, one copy of the 7.3kb chromosome 1 fragment and no copies of the 7kb der (11) fragment were obtained.

cDNA Library Screening

20-26 week foetal brain and 20-25 week foetal heart 5'-STRETCH PLUS cDNA libraries, constructed in lambda gt10 and gt11 respectively, were obtained from Clontech and screened according to the manufacturers instructions. Inserts were obtained from pure clones using two methods. Firstly, cDNAs were amplified by PCR, turbocloned (1993, Nucleic Acids Res. 21: 817-821) and sequenced. Due to the probable introduction of sequence alterations during PCR, several subclones were sequenced. Alternatively, lambda DNA was digested with *EcoRI* to release the cDNA insert which was then subcloned into *EcoRI*-digested pBluescript SK (-) (Stratagene).

Polymerase Chain Reactions

PCR was carried out using AmpliTaq DNA polymerase (Perkin Elmer). Each 50 microlitre reaction contained 1 unit of enzyme, 300ng of each primer, 200mM of each dNTP, 1.5mM MgCl₂, 50mM KCl and 10mM Tris-HCl pH8.3. A probe corresponding to nucleotides 1177-1321 of DIS1 was prepared from cloned cDNA using primers ACGTTACAACAAAGATTAGAAGACCTGG and TGCTGAGTGGCCCCACGGCGCAAG, with touchdown PCR (75°C-65°C) and 30s denaturation at 94°C, 30s synthesis at 72°C. Marker *D1S251* was mapped by PCR using the standard cycling conditions for this marker.

A probe containing the DIS1 exon predicted by NIX was prepared by PCR using the wt1 fragment as template and primers CCATTTCTGGACGGCTAAAGACC & GCARACACTTTGGCTAAGGCGGC (694bp product). The cycling conditions used were: 35 cycles of: 94°C, 30s; 58°C, 60s; 72°C, 60s. Amplification from DIS1 cDNA was performed using proximal primers CCAGAGCGTGACATGCATTC &

CCAGGTCTTCTAATCTTTGTTGTAACGT (292bp product from 35 cycles of: 94°C, 30s; 62°C, 60s; 72°C, 30s) and distal primers GGAAGCTTGTCGATTGCTTATCC & AGATCTTCATCATGACTGTGGATTGC (270 & 336bp products from 35 cycles of: 94°C, 30s; 64°C, 60s; 72°C, 30s). An initial hot start step was carried out. This involved preparation of two separate mixes, one containing template, buffer and nucleotides, and the other containing enzyme and primers. These were incubated at 90°C separately for two minutes prior to mixing and cycling.

In order to amplify cDNA inserts from lambda vectors, a single plaque was picked into 25 microlitres of distilled water. 1-5 microlitres were then added to a PCR reaction and the cDNA insert amplified using vector-based primers. Lambda gt10-specific primers, AGCAAGTTCAGCCTGGTTAAGT & GGGACCTTCTTTATGAGTATT (35 cycles of: 94°C, 30s; 68°C, 60s; 72°C, 180s) and lambda gt11-specific primers GAAGGCACATGGCTGAATATCGACGGTTTC & GACACCAGACCAACTGGTAATGGTAGCGAC (35 cycles of 94°C, 30s; 56°C, 60s; 72°C, 90s) were used to amplify inserts from the foetal brain and foetal heart cDNA libraries respectively.

Hybridisation

Standard procedures were used for Southern blotting and hybridisation (Sambrook et al., *Molecular Cloning: A laboratory Manual.* 2nd Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1989). Probes were labelled with alpha ³²P-dCTP by random priming using High Prime (Boehringer Mannheim) and purified using Pharmacia NICK columns. The oligonucleotide probe was labelled with gamma ³²P-dATP. Oligonucleotide hybridisations were carried out overnight at the appropriate temperature.

Subcloning

Exon 4 of DIS1 (and flanking DNA) was subcloned from cosmid ICRFc112D2299QD4 by digestion with *EcoRI*. Digested fragments were subcloned into *EcoRI*-digested pBluescript SK (-) (Sratagene) and subclones containing the exon were identified by hybridisation with the DIS1 cDNA nucleotide 1177-1321 probe. The exon was found to be contained within a fragment of approximately 4kb.

Claims

A substantially pure polynucleotide, encoding the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 3 or their isoforms.

5

- Polynucleotide according to claim 1, comprising the sequence according to SEQ ID NO: 1.
- 3 A recombinant expression vector comprising the polynucleotide according claim 10 1 or 2 or fragments thereof.
 - 4 A polypeptide according to SEQ ID NO: 2 or SEQ ID NO: 3 or their isoforms.
- 5 Cell line transformed with a polynucleotide encoding at least part of the 15 polypeptide according to claim 4
 - 6 Cell line transformed with a polynucleotide according to claim 1 or 2 or fragments thereof or transformed with the expression vector of claim 3.
- 20 7 Cell line according to claim 6 of mammalian origin
 - 8 Cell line according to claim 6 or 7 expressing a DIS1 gene product, wherein DIS1 gene is defined as a stretch of DNA
 - a) of approximately 300 kB on chromosome 1, spanning the breakpoint of a balanced t(1;11)(q42.1;q14.3) translocation and
 - b) hybridisable to the polynucleotide sequence according to SEQ ID NO: 1 and/or SEQ ID NO:4
- 9 Use of a polynucleotide hybridisable to the DIS1 gene in the in vitro diagnosis of 30 a psychiatric disorder, wherein DIS1 gene is defined as a stretch of DNA
 - a) of approximately 300 kB on chromosome 1, spanning the breakpoint of a balanced t(1;11)(q42.1;q14.3) translocation and

- b) hybridisable to the polynucleotide sequence according to SEQ ID NO: 1 and/or SEQ ID NO:4
- 10 Use of a cell line according to claim 6 to 8 in the in vitro diagnosis of a psychiatricdisorder.
 - 11 Use of a polypeptide encoded by a polynucleotide comprising SEQ ID NO 1 or fragments thereof in the in vitro diagnosis of a psychiatric disorder.
- 10 12 Use of a polynucleotide according to claims 1 or 2 or fragments thereof or the expression vector of claim 3 in a screening assay for the identification of new drugs.
- 13 Use of a polypeptide according to claim 4 or analogues or fragments thereof in a screening assay for the identification of drugs for the treatment of psychiatric disorders.
 - 14 Use of a cell line according to claims 6 to 8 in a screening assay for the identification of new drugs for the treatment of psychiatric disorders.
 - 15 A polynucleotide comprising SEQ ID NO 1 or fragments thereof for use as a medicament.

- 16 A polypeptide encoded by a polynucleotide comprising SEQ ID NO 1 or fragments thereof for use as a medicament
 - 17 A polynucleotide comprising SEQ ID NO 1 or fragments thereof for use as a medicament for the treatment of a psychiatric disorder.
- 30 18 A polypeptide encoded by a polynucleotide comprising SEQ ID NO 1 or fragments thereof for use as a medicament for the treatment of a psychiatric disorder

- 19 Use of a polynucleotide comprising SEQ ID NO 1 or fragments thereof in the preparation of a medicament for the treatment of a psychiatric disorder
- 5 20 Use of a polypeptide encoded by a polynucleotide comprising SEQ ID NO 1 or fragments thereof in the preparation of a medicament for the treatment of a psychiatric disorder
 - 21 Antibodies against the polypeptide according to claim 4

10

- 22 Pair of oligonucleotide primers for the amplification of a region containing a breakpoint involved in a balanced t(1;11)(q42.1;q14.3) translocation of chromosome 1 and chromosome 11, wherein a first primer is hybridisable to chromosome 1 or chromosome 11 and is located 5' of the breakpoint and a second primer which is also hybridisable to chromosome 1 or chromosome 11 is located 3' of the breakpoint.
- 23 Pair of oligonucleotide primers according to claim 22 wherein at least one of said primers is capable of hybridising to a sequence according to SEQ ID NO 4.

20

30

- 24 Pair of oligonucleotide primers according to claim 22 wherein at least one of said primers comprises the sequence of SEQ ID NO: 5 or SEQ ID NO: 6.
- 25 Method for the detection of a mutation in the DIS1 gene in a given subject 25 comprising the steps of
 - a) providing a set of oligonucleotide primers capable of hybridising to the nucleotide sequence of the DIS1 gene
 - b) obtaining a sample containing nucleic acid from the subject
 - amplifying a region flanked by the primer set of step 1 using a nucleic acid amplification method
 - d) detecting whether the amplified region contains a mutation by

e) comparing the amplified sequence with the sequence of normal control subjects.

wherein DIS1 gene is defined as a stretch of DNA

- of approximately 300 kB on chromosome 1, spanning the breakpoint of a balanced t(1;11)(q42.1;q14.3) translocation and
- hybridisable to the polynucleotide sequence according to SEQ ID NO: 1 and/or SEQ ID NO:4
- 26 A method for identifying ligands for DIS1 gene products, said method comprising the steps of:
 - a) introducing into a suitable host cell a polynucleotide according to claims 1 or 2 or an expression vector according to claim 3 or fragments thereof,
 - b) culturing cells under conditions to allow expression of the DNA sequence
 - c) optionally isolating the expression product
- d) bringing the expression product (or the host cell from step b)) into contact with potential ligands which will possibly bind to the protein encoded by said DNA from step a);
 - e) establishing whether a ligand has bound to the expressed protein.
 - f) Optionally isolating and identifying the ligand

20

25

5

- 27 Method for the detection of a balanced t(1;11)(q42.1;q14.3) translocation in a given subject comprising the steps of
 - a) providing a set of oligonucleotide primers according to claim 22
 - b) obtaining a sample containing nucleic acid from the subject
- c) amplifying a region flanked by the set of oligonucleotide primers of step a)
 using a nucleic acid amplification method
 - d) detecting whether the translocation has occurred by
 - e) comparing the amplified sequence with the sequence of normal control subjects.


30

28 Method according to claim 27 wherein the set of oligonucleotide primers comprises at least one primer comprising SEQ ID NO: 5 or SEQ ID NO: 6,

Figures 1/2 Fig. 1		wt 1 1	der(1	der (1)	wt1		
		~ATTTTTAAATGATACTGAGATATCA:TGTATCAG	der(11)~ATTTTTAAATGATACTGAGATATCATGTAAA) ~ACACGTCATCATCCTGTGAACCATTGAAGT	~ACACGTCATCATCCTGTGAACCATTGAAGT		BREAKPOINT
	TCATTTCTTCCCTCATTTATTCA~	TCATTTCTTCCCTCATTTATTCA~			TGATGGGAGGCAACTTTTTCT~	TGATGGGAGGCAACTTTTTCT~	INT
	der(1)	wt11	NTUTE SHEE	ET (RULE 26)	wt1	der (11)	
			· - · · · - ·	,			

Figures 2/2

Fig. 2



SUBSTITUTE SHEET (RULE 26)

SEQUENCE LISTING

<110> AKZO NOBEL NV
<120> Genes disrupted in schizophrenia
<130> Schizophrenia genes
<140>
<141>
<160> 6
<170> PatentIn Ver. 2.1
<210> 1
<211> 7063

<400> 1

<212> DNA <213> human

ggaaggagca ggaggcagcc caggcggagc gggaggagct ggcagcgggg cgcatqccaq 60 gegggggtee teagggegee ceageegeeg eeggeggegg eggegtgage cacegegeag 120 geageeggga ttgcttacca cetgeagegt gettteggag geggeggetg geaeggagge 180 egggetaeat gagaageteg acagggeetg ggategggtt cettteecea geagtgggea 240 cactgtteeg gtteecagga ggggtgtetg gegaggagte ccaccacteg gagteeaggg 300 ccagacagtg tggccttgac tcgagaggcc tcttggtccg gagccctgtt tccaagagtg 360 cagcageece tactgtgace tetgtgagag gaacetegge geaetttggg atteagetea 420 gaggtggcac cagattgcct gacaggctta gctggccgtg tggccctggg agtgctgggt 480 ggcagcaaga gtttgcagcc atggatagtt ctgagaccct ggacgccagc tgggaggcag 540 cctgcagcga tggagcaagg cgtgtccggg cagcaggctc tctgccatca gcaqagttqa 600 gtagcaacag etgcagecet ggctgtggce etgaggtece eccaacecet eetggetete 660 acagtgeett tacctcaage tttagettta tteggetete gettggetet geeggggaac 720 gtggagaage agaaggetge ceaccateca gagaggetga gteccattge caqaqeeece 780 aggagatggg agccaaagct gccagcttgg acgggcctca cgaggacccg cgatgtctct 840 etcageeett cagtetettg getacaeggg tetetgeaga ettggeeeag geegeaagga 900 acagetecag gecagagegt gacatgeatt etttaccaga catggaceet ggeteeteca 960 gttetetgga teceteactg getggetgtg gtggtgatgg gageagegge teaggggatg 1020 eccactettg ggacaccetg etcaggaaat gggagecagt getgegggae tgeetgetga 1080 gaaaccggag gcagatggag gtaatatcct taagattaaa acttcagaaa cttcaggaag 1140 atgcagttga gaatgatgat tatgataaag ctgagacgtt acaacaaaga ttagaagacc 1200 tggaacaaga gaaaatcage etgcacttte aactteette aaggeageca getettagea 1260 gtttcctggg tcacctggca gcacaagtcc aggctgcett gcgccgtggg gccactcagc 1320 aggecagegg agatgacace cacaceccac tgagaatgga geegaggetg ttggaaceca 1380 agcagctaca gaaagaaatc gaagctctcc aagcaaggat gtttgtgctg gaagccaaag 1500 atcaacagct gagaagggaa atagaggagc aagagcagca actccagtgg cagggctgcg 1560 acctgacece actggtgggc cagetgteec tgggtcaget gcaggaggtc agcaaggcct 1620

					ccggaaacca	
taaggagcct	ccaggaaaga	ataaaatccc	tcaacttgtc	acttaaagaa	atcactacta	1740
aggtgtgtat	gagtgagaaa	ttctgcagca	ccctgaggaa	gaaagttaac	gatattgaaa	1800
cccaactacc	agccttgctt	gaagccaaaa	tgcatgccat	atcaggaaac	catttctgga	1860
cggctaaaga	cctcaccgag	gagattagat	cattaacatc	agagagaa	gggctggagg	1920
gactcctcag	caagctgttg	gtgttgagtt	ccaggaatgt	caaaaagctg	ggaagtgtta	1980
aagaagatta	caacagactg	agaagagaag	tggagcacca	ggagactgcc	tatgaaacaa	2040
gtgtgaagga	aaatactatg	aagtacatgg	aaacacttaa	gaataaactg	tgcagctgca	2100
agtgtccact	gcttgggaaa	gtgtgggaag	ctgacttgga	agcttgtcga	ttgcttatcc	2160
agtgcctaca	gctccaggaa	gccaggggaa	gcctgtctgt	agaagatgag	aggcagatgg	2220
atgacttaga	gggagctgct	cctcctattc	ccccaggct	ccactccgag	gataaaagga	2280
agaccccttt	gaaggtattg	gaagaatgga	agactcacct	catcccctct	ctgcactgtg	2340
ctggaggtga	acagaaagag	gaatcttaca	teetttetge	agaacttgga	gaaaagtgtg	2400
aagacatagg	caagaagcta	ttgtacttgg	aagatcaact	tcacacagca	atccacagtc	2460
atgatgaaga	tctcattcag	tctctcagga	gggagctcca	gatggtgaag	gaaactctgc	2520
aggccatgat	cctgcagctc	cagccagcaa	aggaggcggg	agaaagagaa	gctgcagctt	2580
cctgcatgac	agctggtgtc	cacgaagcac	aagcctgagg	agtgacggga	tgggggaggg	2640
					atagctaaga	
					ggtggttcat	
					gagagagact	
					cattcttggg	
					agaagttggg	
-					caacgaaaat	
					catcatacct	
_					gtctggagtt	
=					ttaatatgca	
=					ctttcaattt	
					gtttcatcag	
	-				gtataaaatg	
_					agtgcagcat	
					aatacagtac	
					caatactcag	
					attcagtaag	
					actcaggaat	
					agtgcagtac	
					cagtactcag	
					tggtactcag	
					cagtgctcag	
					tagtactcag	
					ggcaatgtag	
					ctgctgggct	
					gatttcaatt	
					tctaaacaaa	
					atctgcttgg	
					ggaaactcac	
					tttcatgtaa	
-					aggaagtccc	
	_	_			agagtgttga	
ay cocaaact	Lugarriaca	Juliana			-3-3-3-54	-500

gcttaataac	tacctgccac	agattggtaa	atttaatcca	gtggttgttc	tgtttgtgct	4560
tctgttctca	tttatgtgtt	tagggatagt	gaggttcctg	ccttcactag	gatccacgga	4620
tatgagacca	tttttgtcat	ttcctgaagt	cacactggcg	tttccagaag	gcatctggtg	4680
ctttgctcag	ccttccatgc	tgtgcagcac	ttctgtcctc	agtcaaggag	atggccatgc	4740
ttaagccagc	aattggctgg	ggtccaggaa	acaaagcaaa	agcacaatat	gtgaatgtgc	4800
tgattgtgtt	ccctatggct	ttatctcgag	caaaatacac	tctacatatt	ttaataataa	4860
gtataattag	cttgttcctg	gacttcattt	tcaatgatga	accaaattcc	tgaattattt	4920
ataattgtgt	ctaaagaaaa	ttatgaactg	gtcacatggc	acttggaatc	cttgagttaa	4980
ttccagtgaa	gcaaaacttg	ggaagagtca	ggattggcca	cattgccaat	aacaaattcc	5040
tacttcgaca	tatgtctttt	caaaaagcct	cccagacaca	agacatctta	accgtcacta	5100
gcccaagtgt	tttgtattac	tcagacacca	tcatgaaata	attctgtgag	gtcatgatgt	5160
atttgaaaat	tctgcaagtt	aataactgcc	ttgaattgtt	tgaacccgaa	ataagggttc	5220
tttggtacct	ctagtagata	gtgtgttcat	ttccctgctg	caaattttga	agtatttggg	5280
caggtgagtc	atgttttaac	cacaagccat	aactcatctg	ttgtctttgc	ttggtcttag	5340
agtatcattc	agaaagtccg	ctaagggcca	gcgtgcttct	tctggctaca	caaccttctc	5400
aggacaagcc	cactgtctta	agccactttg	accctgggag	acacaggact	gtgtatcctc	5460
aatcatacta	tacagcagtt	tttgtcaggg	gaacataaaa	atatccaaga	gaggttaggg	5520
cttagattta	aaagcatcaa	aacaacaaca	atggaaattt	atgttggcga	tagccaagac	5580
cacaagcaaa	agcacatact	ggaaatgatg	agttagaatc	tgatttgact	gggatgtttt	5640
atgagaatgt	aagtgtgata	ttatactgtc	tgccttgctg	gaatgctggc	tttcaaatgg	5700
tcacccattt	ttctttcact	ggcctgagtt	aggacatgct	atcagtaata	gtcccagttc	5760
catccaactt	tctgaaattt	cattttttt	tttgagatgg	agtctctctc	tgtcacccaa	5820
gttggagtgc	agtggccccg	caatctcggc	tcactgcaac	ctctacctcc	caggttcaag	5880
ctattctact	gcctcagcct	cccaagtagc	tggggttaca	ggcatttgcc	accgggccct	5940
gatgatttt	gtatttttag	tagagacagg	gcttcaccat	gttggctagg	agggtctcaa	6000
actcctgacc	tcaggcgatc	CACCCCCACC	tcggcttccc	aaagtgctga	gattacaggt	6060
gtgagccacc	gcacccggcc	aactttctga	aatttcaaaa	ctgaattgat	ccttctccaa	6120
attagtatat	actattggaa	acttgtcttt	ccctgcagta	aggctggttt	CCCCACCCCA	6180
gaaacatgta	acggttggta	ccatgctaag	cccttgccat	gctaagccct	ttacagtcat	6240
atcctataat	ccccatatca	accttataag	gaaggtgttt	gtagatgatg	caactgagcc	6300
ttaagaggac	taattccctt	tttctaaggc	acagagetgg	tamaatgtga	agtaatagtg	6360
aacctaacag	tcagagacag	gcagcatgct	cttaactagt	gctcttccta	aagttccttt	6420
aatgtccttt	tgagattttg	agccatggaa	cttacttgtt	cacctggcta	agaactcatg	6480
gccactgtgg	aaatcttggt	tagggagtca	aagaaactga	gcctggggca	aacgaggctt	6540
cccacactgc	caggggagcc	tcactgtgaa	gtctaggctc	agacaggcat	caacaaacct	6600
attcacccca	ccatcatcct	gatctaacca	ttccccagtc	atcccaggaa	aaccactcac	6660
agcctgacac	tgggctgact	ttcttgaaga	tcctcatcca	attggtgttt	ttcagaagtg	6720
	•		_	_	tggtcaatgc	
	•				ctaatctttg	
aattttgtca	tgtaatttat	tgcttcatta	aggttacttt	ttgttataca	aaataaaagc	6900
•			-		ggatgataga	
	33				tgtacagtta	7020
catcacatga	aacatttata	ataaagtcat	gctttagaat	tgc		7063

<210> 2

<211> 854

<212> PRT

<213> human

<4	0	0	>	2

Met Pro Gly Gly Gly Pro Gln Gly Ala Pro Ala Ala Ala Gly Gly Gly

1 5 10 15

Gly Val Ser His Arg Ala Gly Ser Arg Asp Cys Leu Pro Pro Ala Ala 20 25 30

Cys Phe Arg Arg Arg Leu Ala Arg Arg Pro Gly Tyr Met Arg Ser
35 40 45

Ser Thr Gly Pro Gly Ile Gly Phe Leu Ser Pro Ala Val Gly Thr Leu
50 55 60

Phe Arg Phe Pro Gly Gly Val Ser Gly Glu Glu Ser His His Ser Glu 65 70 75 80

Ser Arg Ala Arg Gln Cys Gly Leu Asp Ser Arg Gly Leu Leu Val Arg 85 90 95

Ser Pro Val Ser Lys Ser Ala Ala Ala Pro Thr Val Thr Ser Val Arg 100 105 110

Gly Thr Ser Ala His Phe Gly Ile Gln Leu Arg Gly Gly Thr Arg Leu 115 120 125

Pro Asp Arg Leu Ser Trp Pro Cys Gly Pro Gly Ser Ala Gly Trp Gln 130 135 140

Gln Glu Phe Ala Ala Met Asp Ser Ser Glu Thr Leu Asp Ala Ser Trp 145 150 155 160

Glu Ala Ala Cys Ser Asp Gly Ala Arg Arg Val Arg Ala Ala Gly Ser 165 170 175

Leu Pro Ser Ala Glu Leu Ser Ser Asn Ser Cys Ser Pro Gly Cys Gly
180 185 190

Pro Glu Val Pro Pro Thr Pro Pro Gly Ser His Ser Ala Phe Thr Ser 195 200 205

Ser Phe Ser Phe Ile Arg Leu Ser Leu Gly Ser Ala Gly Glu Arg Gly 210 215 220

Glu Ala Glu Gly Cys Pro Pro Ser Arg Glu Ala Glu Ser His Cys Gln 225 230 235 240

Ser	Pro	Gln	Glu	Met 245	Gly	Ala	Lys	Ala	Ala 250	Ser	Leu	Asp	Gly	Pro 255	His
	_	_		_	_	_							_		
Glu	Asp	Pro	Arg 260	Сув	Leu	Ser	Gln	Pro 265	Phe	Ser	Leu	Leu	Ala 270	Thr	Arg
Val	Ser	Ala 275	Asp	Leu	Ala	Gln	Ala 280	Ala	Arg	Asn	Ser	Ser 285	Arg	Pro	Glu
Arg	As p 290	Met	His	Ser	Leu	Pro 295	Asp	Met	Asp	Pro	Gly 300	Ser	Ser	Ser	Ser
Leu 305	Авр	Pro	Ser	Leu	Ala 310	Gly	Сув	Gly	Gly	Asp 315	Gly	Ser	Ser	Gly	Ser 320
Gly	As p	Ala	His	Ser 325	Trp	жр	Thr	Leu	Leu 330	Arg	Lys	Trp	Glu	Pro 335	Val
Leu	Arg	Asp	Cys 340	Leu	Leu	Arg	Asn	Arg 345	Arg	Gln	Met	Glu	Val 350	Ile	Ser
Leu	Arg	Leu 355	Lys	Leu	Gln	Lys	Leu 360	Gln	Glu	Asp	Ala	Val 365	Glu	Asn	qaA
As p	Tyr 370	Asp	Lys	Ala	Glu	Thr 375	Leu	Gln	Gln	Arg	Leu 380	Glu	As p	Leu	Glu
Gln 385	Glu	Lys	Ile	Ser	Leu 390	His	Phe	Gln	Leu	Pro 395	Ser	Arg	Gln	Pro	Ala 400
Leu	Ser	Ser	Phe	Leu 405	Gly	His	Leu	Ala	Ala 410	Gln	Val	Gln	Ala	Ala 415	Leu
Arg	Arg	Gly	Ala 420	Thr	Gln	Gln		Ser 425	Gly	Авр	Двр	Thr	His 430	Thr	Pro
Leu	Arg	Met 435	Glu	Pro	Arg	Leu	Leu 440	Glu	Pro	Thr	Ala	Gln 445	Asp	Ser	Leu
His	Val 450	Ser	Ile	Thr	Arg	Arg 455	As p	Trp	Leu	Leu	Gln 460	Glu	Lys	Gln	Gln
Leu 465	Gln	Lys	Glu	Ile	Glu 470	Ala	Leu	Gln	Ala	Arg 475	Met	Phe	Val	Leu	Glu 480
Ala	Lys	qaA	Gln	Gln 485	Leu	λrg	Arg	Glu	Ile 490	Glu	Glu	Gln	Glu	Gln 495	Gln

Leu Gln Trp Gln Gly Cys Asp Leu Thr Pro Leu Val Gly Gln Leu Ser Leu Gly Gln Leu Gln Glu Val Ser Lys Ala Leu Gln Asp Thr Leu Ala Ser Ala Gly Gln Ile Pro Phe His Ala Glu Pro Pro Glu Thr Ile Arg Ser Leu Gln Glu Arg Ile Lys Ser Leu Asn Leu Ser Leu Lys Glu Ile Thr Thr Lys Val Cys Met Ser Glu Lys Phe Cys Ser Thr Leu Arg Lys Lys Val Asn Asp Ile Glu Thr Gln Leu Pro Ala Leu Leu Glu Ala Lys Met His Ala Ile Ser Gly Asn His Phe Trp Thr Ala Lys Asp Leu Thr Glu Glu Ile Arg Ser Leu Thr Ser Glu Arg Glu Gly Leu Glu Gly Leu Leu Ser Lys Leu Leu Val Leu Ser Ser Arg Asn Val Lys Lys Leu Gly Ser Val Lys Glu Asp Tyr Asn Arg Leu Arg Arg Glu Val Glu His Gln Glu Thr Ala Tyr Glu Thr Ser Val Lys Glu Asn Thr Met Lys Tyr Met Glu Thr Leu Lys Asn Lys Leu Cys Ser Cys Lys Cys Pro Leu Leu Gly Lys Val Trp Glu Ala Asp Leu Glu Ala Cys Arg Leu Leu Ile Gln Cys Leu Gln Leu Gln Glu Ala Arg Gly Ser Leu Ser Val Glu Asp Glu Arg Gln Met Asp Asp Leu Glu Gly Ala Ala Pro Pro Ile Pro Pro Arg Leu

His Ser Glu Asp Lys Arg Lys Thr Pro Leu Lys Val Leu Glu Glu Trp

Lys Thr His Leu Ile Pro Ser Leu His Cys Ala Gly Gly Glu Gln Lys
755 760 765

Glu Glu Ser Tyr Ile Leu Ser Ala Glu Leu Gly Glu Lys Cys Glu Asp 770 775 780

Ile Gly Lys Lys Leu Leu Tyr Leu Glu Asp Gln Leu His Thr Ala Ile
785 790 795 800

His Ser His Asp Glu Asp Leu Ile Gln Ser Leu Arg Arg Glu Leu Gln 805 810 815

Met Val Lys Glu Thr Leu Gln Ala Met Ile Leu Gln Leu Gln Pro Ala 820 825 830

Lys Glu Ala Gly Glu Arg Glu Ala Ala Ala Ser Cys Met Thr Ala Gly 835 840 845

Val His Glu Ala Gln Ala 850

<210> 3

<211> 832

<212> PRT

<213> human

<400> 3

Met Pro Gly Gly Gly Pro Gln Gly Ala Pro Ala Ala Ala Gly Gly Gly

1 5 10 15

Gly Val Ser His Arg Ala Gly Ser Arg Asp Cys Leu Pro Pro Ala Ala 20 25 30

Cys Phe Arg Arg Arg Leu Ala Arg Arg Pro Gly Tyr Met Arg Ser
35 40 45

Ser Thr Gly Pro Gly Ile Gly Phe Leu Ser Pro Ala Val Gly Thr Leu 50 55 60

Phe Arg Phe Pro Gly Gly Val Ser Gly Glu Glu Ser His His Ser Glu 65 70 75 80

Ser Arg Ala Arg Gln Cys Gly Leu Asp Ser Arg Gly Leu Leu Val Arg 85 90 95

Ser Pro Val Ser Lys Ser Ala Ala Pro Thr Val Thr Ser Val Arg

PCT/EP00/11915 WO 01/40301

			100					105					110		
Gly	Thr	Ser 115	Ala	His	Phe	Gly	11e 120	Gln	Leu	λrg	Gly	Gly 125	Thr	Arg	Leu
Pro	As p 130	Arg	Leu	Ser	Trp	Pro 135	Сув	Gly	Pro	Gly	Ser 140	Ala	Gly	Trp	Glı
Gln 145	Glu	Phe	Ala	Ala	Me t 150	Asp	Ser	Ser	Glu	Thr 155	Leu	Asp	Ala	Ser	Trp
Glu	Ala	Ala	Сув	Ser 165	Авр	Gly	Ala	A rg	Arg 170	Val	Arg	Ala	Ala	Gly 175	Ser
Leu	Pro	Ser	Ala 180	Glu	Leu	Ser	Ser	As n 185	Ser	Сув	Ser	Pro	Gly 190	Сув	Gly
Pro	Glu	Val 195	Pro	Pro	Thr	Pro	Pro 200	Gly	Ser	His	Ser	Ala 205	Phe	Thr	Sez
Ser	Phe 210	Ser	Phe	Ile	Arg	Leu 215	Ser	Leu	Gly	Ser	Ala 220	Gly	Glu	Arg	Gl3
Glu 225	Ala	Glu	Gly	Сув	Pro 230	Pro	Ser	Arg	Glu	Ala 235	Glu	Ser	His	Сув	Gl: 240
Ser	Pro	Gln	Glu	Met 245	Gly	Ala	Lys	Ala	Ala 250	Ser	Leu	Asp	Gly	Pro 255	Hie
Glu	Авр	Pro	Arg 260	Сув	Leu	Ser	Gln	Pro 265	Phe	Ser	Leu	Leu	Ala 270	Thr	Arg
Val	Ser	Ala 275	Asp	Leu	Ala	Gln	Ala 280	Ala	Arg	Asn	Ser	Ser 285	Arg	Pro	Glu
Arg	А вр 290	Met	His	Ser	Leu	Pro 295	Asp	Met	Авр	Pro	Gly 300	Ser	Ser	Ser	Sei
Leu 305	Asp	Pro	Ser	Leu	Ala 310	Gly	Сув	Gly	Gly	А вр 315	Gly	Ser	Ser	Gly	Se:
Gly	Asp	Ala	His	Ser 325	Trp	Asp	Thr	Leu	Leu 330	Arg	Lys	Trp	Glu	Pro 335	Va]
Leu	Arg	Asp	Сув 340	Leu	Leu	Arg	Asn	Arg 345	Arg	Gln	Met	Glu	Val 350	Ile	Se

Leu Arg Leu Lys Leu Gln Lys Leu Gln Glu Asp Ala Val Glu Asn Asp

Asp Tyr Asp Lys Ala Glu Thr Leu Gln Gln Arg Leu Glu Asp Leu Glu Gln Glu Lys Ile Ser Leu His Phe Gln Leu Pro Ser Arg Gln Pro Ala Lou Ser Ser Phe Leu Gly His Leu Ala Ala Gln Val Gln Ala Ala Leu Arg Arg Gly Ala Thr Gln Gln Ala Ser Gly Asp Asp Thr His Thr Pro Leu Arg Met Glu Pro Arg Leu Leu Glu Pro Thr Ala Gln Asp Ser Leu His Val Ser Ile Thr Arg Arg Asp Trp Leu Leu Gln Glu Lys Gln Gln Leu Gln Lys Glu Ile Glu Ala Leu Gln Ala Arg Met Phe Val Leu Glu Ala Lys Asp Gln Gln Leu Arg Arg Glu Ile Glu Glu Gln Gln Gln Leu Gln Trp Gln Gly Cys Asp Leu Thr Pro Leu Val Gly Gln Leu Ser Leu Gly Gln Leu Gln Glu Val Ser Lys Ala Leu Gln Asp Thr Leu Ala Ser Ala Gly Gln Ile Pro Phe His Ala Glu Pro Pro Glu Thr Ile Arg Ser Leu Gln Glu Arg Ile Lys Ser Leu Asn Leu Ser Leu Lys Glu Ile Thr Thr Lys Val Cys Met Ser Glu Lys Phe Cys Ser Thr Leu Arg Lys Lys Val Asn Asp Ile Glu Thr Gln Leu Pro Ala Leu Leu Glu Ala Lys

Glu Glu Ile Arg Ser Leu Thr Ser Glu Arg Glu Gly Leu Glu Gly Leu

Met His Ala Ile Ser Gly Asn His Phe Trp Thr Ala Lys Asp Leu Thr

610 615 620

Leu Ser Lys Leu Leu Val Leu Ser Ser Arg Asn Val Lys Lys Leu Gly 625 630 635 640

Ser Val Lys Glu Asp Tyr Asn Arg Leu Arg Arg Glu Val Glu His Gln 645 650 655

Glu Thr Ala Tyr Glu Thr Ser Val Lys Glu Asn Thr Met Lys Tyr Met 660 665 670

Glu Thr Leu Lys Asn Lys Leu Cys Ser Cys Lys Cys Pro Leu Leu Gly 675 680 685

Lys Val Trp Glu Ala Asp Leu Glu Ala Cys Arg Leu Leu Ile Gln Cys 690 700

Leu Gln Leu Gln Glu Ala Arg Gly Ser Leu Ser Val Glu Asp Glu Arg
705 710 715 720

Gln Met Asp Asp Leu Glu Gly Ala Ala Pro Pro Ile Pro Pro Arg Leu
725 730 735

His Ser Glu Asp Lys Arg Lys Thr Pro Leu Lys Glu Ser Tyr Ile Leu
740 745 750

Ser Ala Glu Leu Gly Glu Lys Cys Glu Asp Ile Gly Lys Lys Leu Leu 755 760 765

Tyr Leu Glu Asp Gln Leu His Thr Ala Ile His Ser His Asp Glu Asp
770 780

Leu Ile Gln Ser Leu Arg Arg Glu Leu Gln Met Val Lys Glu Thr Leu 785 790 795 800

Gln Ala Met Ile Leu Gln Leu Gln Pro Ala Lys Glu Ala Gly Glu Arg 805 810 815

Glu Ala Ala Ser Cys Met Thr Ala Gly Val His Glu Ala Gln Ala 820 825 830

<210> 4
<211> 33780

<212> DNA <213> human

<400> 4

ttcctgacat ttccgggtgc gggacggcgt taccagaaac tcagaaggtt cgtccaacca 60 aaccgactct gacggcagtt tacgaagaga gatgataggg tetgetteag taagccagat 120 gctacacaat taggcttgta catattgtcg ttagaacgcg gctacaatta atacataacc 180 ttatgtatca tacacatacg atttaggtga cactatagaa tactaggatc ttccctccac 240 etcectetgt egeceagget ggagtgeagt ggeatgatat eggeteactg caagetetge 360 etecegggtt eacgecatte teetgeetea geeteceaag tagetgggae tacaqqeqee 420 tgccaccacg ctcggctaat tttttgtatt tttagtagag acggggtttc accgtgttag 480 ccaggatggt ctccatctcc tgaccttgtg atctgcccac ctcggcctcc caaagtgctg 540 ggattacagg cgtgagccac cgcgcctggc cttccacatc tctccttata atgataccag 600 teatattgga ttggggttea cectaatgae tttattttaa atttattace tattgaaaag 660 ccctatctcc aaacategtc acattettag gtactggggg attecggact ccaacetgtg 720 aattttgggg gacacaactc aaccggtgac aggcaccttt gcatttaatt ttcttttgcc 780 acagecacce eccaggetea tetgetgetg atgtgegtte tgtgeageae atteatgtea 840 gtagtctcaa tttttgtaag gtttcatttg ttgagggtga aatttggtca tatgattgga 900 acaccagttt gtgagtaaag aataatgtgt atttacaaat catqatattq attatattgt 960 acattgaaca aaattctgaa atagaattcc aaaaatttgt ctggatgaca gttcatttta 1020 aataggtaca cagcttctgg gagcggtagt tagtattgtt caatagttag gagagcagat 1080 agttagactg cctgggttac tgtttaatct cccataatta ccagctggtt acccctggga 1140 aagttactta aacctctctt agtctctttg atgaaatttt cttgtcttac aatgtagata 1200 attagagttt ctacttcata gagttataat aagaatttaa aatgctcatc tacatagaga 1260 atttgggaga gtgtctggta catagtaagt gttcaataaa tgttggattc tattatttcc 1320 agggcagcca ctttgaatga agatactcat ttgggtaaat taggtctggt gtgtttctga 1380 aaatgtgttc gctaatttgt ttggacaaat tgtgtgtttc tagggtaagg cataatttca 1440 tetgagagga taattettgt ttgttatgaa taatatgeaa gttttttaaa aagtggggat 1500 tggtttcact cattaaagta cacggaactc ctgcttgtca gcattgaact ggtcttattt 1560 tetggttttt ggtttgtagt eetgeteetg gaattaeggt ttggggaeca eagtgtgatg 1620 gcagcagcaa catgtgtgta tgtttggggg actaatgtga catctttgta ccctaggcca 1680 gacaccccac ttcaataaaa gcagattccc tgttatcttt attatgtttt atagtgctgt 1740 gtaaactttg gtttgagaga attcttctac tataaatage etgaaaccca etageatagt 1800 atatagattc ctcatatcgt ctgctccccc aacaattgct tttattctgt atatacccca 1860 gggatacaac taatgttaat agtagcctga gcaaaacgta attgggaagg caaatctgtt 1920 gcaaaaagga atatagcata aattaattat aaatcaaatt aaatataaaa caatgcattt 1980 aattatetge ateaetgeee eetteeteta acatggatat etgagaggag actgatttte 2040 tttctgggat agggccagat ctcagcccag acaagtgaac tgtgtcaacc cctggaaaga 2100 tggtgcttga cctccttttt tgtgatatgt tgggcattag ctaaaggcac tgctgttttg 2160 gtcagetaaa atttcagtat cagtaagagg atctactacc tatctgaatt gttaatgcat 2220 gggctagtct ttgtgtgtga ttgggaacac ctacttataa tatactatta aatgctcata 2280 taggttcaat gatgtgttga accatttatt aaaaatgtat ttgttgaatg gactctaacg 2340 agcccagcaa gggaaagtgc atttctgccc aaggaaggtt ttcagtttgg gcagcaggca 2400 ttagccaccc aaagctggtg ctgctgttag aatcagagga agaaccagta cgggtccatg 2460 ttggatgeec tetgteette teaceacect aagtggttte atetgeecea atetecatgt 2520 ctgtgtgaca ctctgactta tgttctctca aaagatccaa tccctggcca gccagagtct 2580 agcattetee aggeaggatt ccaaacattg ttttecactg tteccactga gtacaegaat 2640

ttttgtcaga	tggcagetee	tgaattctga	agagtctggt	gtcacatgcc	ccacctctgt	2700
		tgggctgatc			-	
aaagtaggtc	taaagtggta	atgactgatt	agtacggacc	tgcaccagtt	cccaggtatt	2820
tacaattgan	acgagtttgc	ttatactcag	aagtgacaaa	atggtggatg	tgataacatc	2880
•	_	gaagaacana		-		
ctccaatact	tggcaacctc	tggtatgaga	tttcctgaca	ccctgcacac	tttcccttcc	3000
ctcccaacac	ataccccaga	accettgace	tttccttttg	caggtcatca	tttaatcaag	3060
taatcactcc	tettetagea	tctgttacat	tttctggcat	ttctagcagc	agtaagtggt	3120
tgagggcagg	aaccatgtct	tcatgctcta	agttcctagc	ttgctgggtg	cccagtagat	3180
agatatttga	agaatgagtg	agttcatgaa	tgcatgaaag	agtggaaaac	tctagaatgg	3240
atgttctcac	tgctgtgagc	atccacgtaa	tccagtcctg	ttetteecte	ccctttctga	3300
cctctatcac	tetgegggge	ccatggaccc	catgacgggc	ttacactgct	gaagaggcct	3360
gtctggtttt	gtcacattca	gactttcttc	ctccaaatca	tctctcatag	tgccgcccaa	3420
ttatttttct	aaaaacaaa	aacacttctt	tcatattgct	ctcttgctag	aaaacggaat	3480
gatttctcat	tgcttgaggg	ataaaactca	aaactcctta	gtctggcatt	taatactgac	3540
tagagettge	ccttgatatt	tctttaaaaa	tattttaatt	gtaaatattt	caaacatatt	3600
taaaaataca	acactcattt	atccactact	aggattaaac	aaatagtaga	atttacccca	3660
tatttacttt	gattttcttt	ccctgactaa	ataaatttat	tttattttat	tttttggaga	3720
tggagtcagg	gtttcaccat	gttggccacg	ctgctcgcga	actcctgact	tcaggtgatc	3780
cacccccaa	ggcctcccaa	agtgctggaa	ttacaggegt	gagccaccac	ggcccggccc	3840
ctaactaact	aaataagcaa	ccattataga	tacagatagg	CCCCaCCCCa	tccttctctc	3900
tcttttccta	ccagaaatag	tcatttccct	gtttatcttt	cacaactcac	ctgtgagaac	3960
catttagtcc	agttagattt	atcttcttgc	tagaatttca	ttctctttt	tttttccctt	4020
tgaggcccag	ttcacttttc	acctcttctg	gtaagctttc	ccaccaatct	cctagttcta	4080
aattgctgca	caagttattt	tctccattgc	tcaaggcaga	caatattctg	cctggtgaca	4140
gcttttatgt	agcagttttc	tcctagtatt	gattttctat	tccccttata	gtaattttt	4200
_		cgaattgcat				
cttcagaata	agatctgact	cttaattgca	ttgattcatt	cattctacag	gtattgactg	4320
agggcttact	aacaagctcc	aggaattctt	taagcactgg	ggatgcagga	gtggacacaa	4380
cagacagtcg	ctgccttcat	ggaacttaag	ttccagtggg	agagagaa	attacatgaa	4440
		aaaagtgcta				
		ctttaaatat				
cgaatgcaga	gggctctggg	tacatatttg	ctgaattgca	ttgtctaccc	aaatagatac	4620
_	• • • •	agacactact	_	_	-	
		teetttgetg				
		gggcatgata				
		ttcctagcac				
		tgcacttctt				
-		gtggtattga				
		caggaaagaa				
		tttatattcc				
		agatettagg				
		ggcccaatga				
		cttgtggaca				
		agggactgaa				
		gggcttggtg				
		atcacctgag				
ttgtgaaacc	ccgtctctcc	tgaaaataca	aaaattagct	gggtgtggtg	gagggtgcct	5520

gtaateeeag etaeteagga ggetgaggta ggagaattge tttaaceeag gtggttgagg 5580 ttgcagtgag cegagattgc accattgcat tecageetgg gagacagage gagactetat 5640 ctcaaagaaa aaaaaaatgc tttcaggatg gtagtaattt gagaaattaa ttacttttct 5700 teccaggagg geaatgtetg gttteeteac aaatagaaca gttggtgaet gtttttttgt 5760 tetttaaage tttteagttg gettgacaat cattttgeet aetttateea tegtttatae 5820 tgccatagea agacettggt ttgtgtacag acagaatacg tetteactat teeetgagag 5880 cacagteaat taaatagtea atgteeteat tagttaggat aaceacagtt tacaaaacaa 5940 aagccettet catatgtatt tatacetgge caagttattg acagactgag aaacaggate 6000 aattactctg tgaattatga ctaaatgttg tggcagagaa ctgggtatga atcattcatt 6060 atttgcagtt ggtctgggaa cgaggggtgg ttgtaccatg gtcgaaatgt aaaaaggaca 6120 gettgetgag cagagageaa egeagetgag ageetgttgg cetggaagga etetetteeg 6180 gtctctgtgc ccagagaaag aaagtcttgg accctagatc aggaaacacg ccaagggatc 6240 accgcagcta agccagaatc agggatgtga tgttggcaaa aatgtctgga gttactctgt 6300 gcattttctc catttctgta tctaatttat ttctgaaaac aacacccagt gattttgcta 6360 aaggtcacag agccgcaggt ttgatgggta attataactt gtgtacaaag agagcttcct 6420 gttaggaaca agtggtgccc gtaagacagc atcggagcca gggacccaga aatgcttgac 6480 ttctgctctg ctcacccaaa ggttctttca cccaggctgg agtgtaatgg catgatcata 6540 geteacteag cettgatete eegggeteag gtaateetee tgeeteagee teecaagtag 6600 ctgggactac agacacatgc taccttgccc agctaaattt gtttgatttt cagtagagac 6660 caggicitige taggitigeed aggicigatet tigaacticitig agdicaageg atoctectige 6720 ctcagtgtgt caaaattggg attgcaggca agagccaccg cacctgcctc tcttacattt 6780 tctgctgttt atcaggtgcg tcctgatttc tatgtagaat taaaagatgg gaggactgtc 6840 ttgggtctga gtttattgac tatcttcaga acatactgta tgggtaatat gaatgcatct 6900 gtacaccaac gttgaggata caggtgtgcc tattatataa tgcagatggt gcttatatgg 6960 gtgtgtgtat gacactgtat attgtggata cacacatata ctgatacgca cccaatatta 7020 ggatttgctg aaaatttcca actactatta aagatcttag attttcccaa atatcaaaaa 7080 tgggttgttt tgtttgcata cagtectact ccatttgagt tgctataaca aagtactgta 7140 gacgaggtgg cttataaaca acagaaattt aattcccatc actttgaagc ctggaagtct 7200 gggattaggg ttccagcatg gctaagttct ggtgagaggc cctcttacag gctgcagacg 7260 gttgacttct tgttgtattc ctgcatggaa gaaagagggc aaggcggggt ctctggggct 7320 tetttataag ggtactaate eeetteatgg gggeeecace tteatgacet gateacetee 7380 caaaggcccc acctcctaat gccatcacct tgggagttag actttcaacc tatgaattct 7440 ggggggaaaa aaacatctcc aaccattgca cataccttct ctaatacatt tataaaactt 7500 tataattact tegettttee ataaaattaa ggaacteaca tetttgattt taaaatgtaa 7560 acataaaagc cccatttgat aatgagttcc ttggtgtcca attttatttg taaataaaaa 7620 ggatacacag gttttccggg gatgtgtatg tgtgtgtgca gaggtggata ggtgtgtgtg 7680 cacagacacg aatgtgtgtg tgtgttgtgg gcaggggcct atattagtcc acagagaatt 7740 aaaacaaac tgtccagtca cacaaaacag ctttctctgt actttaaact agattgacca 7800 gtgaccatga gctgagacca aggtctcagc ttgacatagc tttctttctc tagtgtgtta 7860 ctgatattct ttagactcct gtctcagaaa gaaatgaaac cttccttgca ctcattacat 7980 ttcttaaact cttatgggtt acccaaacca aaagtaatta agggataaat gagatggaag 8040 aaacagttgg aaataaatgg gatatctgga gattggtaga tattagatta catccagcag 8100 agcctgaaag aatgaacatt gcaatttaat aagaagattc agaaaggttg tttagtatta 8160 atattgacag cttgaaagat agatttgctc aacaaaaggg aaaactgact caattatgat 8220 aacagatact gttcactaaa atcagaaata tggacataga ctggatgaaa cataagaaat 8280 atggctggga ttacagagtt aatggaaatg ceetcagace ttagatgaca ttttttaaaa 8340 taatteggte gggattgeee catettttt gttttgacce caatcaaaaa ttggttetet 8400

tggaagagga t						
nnnnnnnnn r						
nnnnnnnnn 1						
nnnnnnnnn I						
cctctcttct t	_					
ttttcatcac c			_		_	
geettetgat t	ttttagctga	ataaatgatg	attcctggtc	atttctctcc	ccctaggtgt	8820
gtatgagtga g	_			_	_	
taccagcett g	gettgaagee	aaaatgcatg	ccatatcagg	taactggcag	tgtaggagac	8940
gttgaagcta t	tccaactaaa	ataatgacag	ctaccagege	atcgtgtttt	gtcctcgatg	9000
aacattccac t	tgttattatg	tcattctcag	acatctgaaa	gcttttctgg	gaagtttcac	9060
taatatgcac a	ataatatagc	acaaggtgtt	taagtgagta	ccgtatttgg	gacttctagt	9120
tectgtttet t	tgaagagttt	agagactaaa	tgtactctgt	gtgccatatg	attctagcag	9180
atgtgtatgt a	agcattgtgt	atctgtaaat	actgaatgag	gattattggg	tgtgatcaga	9240
ccctttctat a						
ctagtcatag a						
ttaaggaatt g	gatttttcca	ttaattagta	gcttgaagtc	aagagtctct	gaaaacagta	9420
tcttatccta t	tcattagtgc	tttcaaacac	tcctctggat	ttgttatttt	attttcacaa	9480
ttgctatatt a	aggtagatgg	gagagagacc	gtgatccgaa	tggactgatg	gggaggttga	9540
ggctgcggga t	tgtgtccttt	ggttaaggtc	actcaattag	ctaagcagtg	gcagatctgg	9600
ggctaaagtc c						
tgacagette a	aaaagttct	ctgagtttta	taggttgaat	ggacccagag	ctcatcagct	9720
tcaaaagaat o	cataaaaatt	taacaaaag	ttataataat	tacatgtatg	tgttttaaat	9780
ggtattttaa g						
aatgttggca g	gctaaagagc	aatttggtcc	ctggtgcagt	cacgcgtatt	atttacaacc	9900
agtagaacat g	ggcagcgcaa	atgtggggct	tggctcttaa	cagcttcaca	tgccatttac	9960
ttgaaattat g					-	
ctgagttagg g	gtttttgcct	ttcttaatca	atatatcttt	cccaggaata	ccggtggatg	10080
agtctgtatt a	agcccaagg	gaagaaatgt	ataattcagg	cagcagagat	agcctcactc	10140
caatgtgaac a					_	
ggcgcaggtt t						
ctgaaggatg a	acctgaatta	accctcctgg	taactgacct	tttgacctca	ctattttctg	10320
gttgctctgt a	atgetetttg	gtggaccggc	ctttcagtca	atgggctgtc	cccatgggtg	10380
atactagtgt t						
tteeteetgt t						
aaaagcccta t						
tcagtcgccc a						
gggttcatac d						
ccacgcccgg (
atggtctcaa 1						
cttaagattc t						
tagactgatt g						
ccccacattc a						
atgctgtttt (
gtagttcttc (
ttgccttccg (
caactaaatc (
gagaaaggac 1	taatacatcc	atcctgactt	tgatctatgg	cctgaggtcc	tttcttaatt	11280

	ttgccatttg			-		
	agctccttta				_	
	caggcattga					
	tctaactaca				-	
	ttttgccact					
	tatccttcac					
	gattttagga					
	tctactgctg					
	gttatttatt					
	ggctcaactg					
tetggetgtt	gagtgctctc	tatgtgggcc	tctctatagg	cagcttggct	tccttacagc	11940
	ggttccaaga					
ttaaggtctg	aattcagaca	ctggtatgca	tctctattaa	tgtgtaataa	gtggctcctc	12060
aaacttcata	gcttgaaaca	acaaaccttt	atctctcaca	gtctctgaga	gacaggagtc	12120
cagagtgact	tagctgggtg	gctctgactc	agggtctcat	aaggtcgctg	ttaagacaca	12180
ctttggagct	gcagtcgtct	aaaggcttgg	ctggggctga	aagatctgct	tccaaactca	12240
tgcatgtgtt	gttaacagac	ggcttcagtt	ccttgccaca	agagctgtgc	cctaggacct	12300
cttgcaacat	agcagctgat	ttcctcagag	ccagtgatct	gagggagaga	gaccaaataa	12360
gacagaagcc	acagatgcca	ggcgcggtgg	ctcacaccta	taatcccagc	actttgggag	12420
gccgaggtgg	gtggatcacg	aggtcaggag	atcaagacca	tcctggctaa	catggtgaaa	12480
ccccgtctct	actaaaaata	caaaaaatta	gctaggcgtc	atggcgggcg	cctgtagtcc	12540
catctactcg	ggaggcggag	gcaggagaat	ggcatgaacc	gggaggcgga	gcttgcggtg	12600
agccgatatc	gcgccactac	actccagcct	gggtgacaga	gcaagactcc	gtctcaaaaa	12660
aaaaaaaaa	aaaaaaaaa a	agccacagtg	tcttgttagg	acttagectt	caaagtcaca	12720
cagcatcact	tctgcttagt	gactagaagc	aagtcactaa	gttcagttca	gcccacaggc	12780
aaggggaagg	aaacaggttt	taccccaaag	gaggagtatt	aaagaatttg	gtgggcatat	12840
ttttataacc	actgcagtgt	tacttccatt	gtgttttatt	ggtccagcat	tcctggtgtg	12900
ctgattcaag	ggaagggcca	ctataacaag	tctcaatgag	aggtgtgtca	aagagtttca	12960
gtgccatgct	ctaaaaagtg	ccacagtatt	tattgagaca	gaaggatttt	gagaactgaa	13020
gacctggaca	gagagctttt	cagtcagagg	aaatggcctg	ttccatttat	ttactgaaaa	13080
gaaaaatatc	atggagcatc	taggaagtgt	cagatctggt	tctaggtact	gaggatgcag	13140
tagagaacag	gacaagatcc	cccttccttt	tttttttt	ttgaggcaag	gtgttgctct	13200
gttacccagg	ctggagtgca	gaggtaagat	catagttgac	tgcagccttg	aattcctagg	13260
ctcaagccat	ccttagcctt	agcctctgga	gtcacgggat	tataggcatg	agctcctggc	13320
tcaatgtctc	ttcttttttg	atagctgtgt	tctcccattg	gccacagtgg	aatggagcta	13380
gatatgcctg	ggctgaatat	ggaggaaaag	ctcagctatt	tcttcaggag	gaagagtagt	13440
ctagattggc	ccaggtatag	gattagtatt	gtggtagctc	ttcagagttg	gttaggacca	13500
ggatacacag	agctctgaat	tgtaggctaa	ggataagagc	attttaggga	gccattacca	13560
tgttttagcg	gagtagtgac	atgattaaaa	ccagacttta	ggaagcgtaa	tccggccatg	13620
ttgtacacag	agggatggat	gtggcaacac	cttgggagtc	atggaattaa	ctaggatgtt	13680
agaaatgaaa	aaaggaagaa	aagtaggcta	gtataggaaa	tctactacag	ataggtaatt	13740
attgatttt	ggaagaacca	tgatgatatt	aatatatcca	gttgagtgtg	gtgtaataca	13800
cattaagaaa	agtaatttag	agagcccatt	gtttctctcc	cttttcactg	tacacacctt	13860
aagtgtgttt	tagtcacctc	ttttttcca	ttctctattt	ctgtttcaat	tttcctgttc	13920
agcagaggat	agtttggttt	aaagccgata	gcaaaagtgg	attctgttgt	tgctgtcctt	13980
cctagacata	tcagtccgtt	ctcacactgc	tgtaaagaaa	tacctgaggc	tgggtaattt	14040
ataaagaaag	gaggtttaat	tggcttatga	ttctgcaaat	tgtacaggaa	gcatggcagc	14100
atctgcttgg	cttctggaga	ggcctcagga	aacttacaat	catggcggaa	ggtgaagggg	14160

					ccacgcactt	
ttaagtagcc	ggaccttgtg	ataactcact	atggcaacag	catcaccaag	agggatggtg	14280
ctaaatcatt	aatgagaaac	tgcccctatg	atccaatcac	cttccactgg	tgctaaatca	14340
					tccagcactg	
					atcactagtg	
aaggaaagta	cagccctgag	ctctatgcat	actgacgtag	aggaagaaac	tcaccagggc	14520
agagagattt	ctcagttttt	gagtgcaggg	gccatacagt	tagtagagag	aaacttgggc	14580
tttggaatct	gagaagtgtg	tgttcaagtg	cagctttatc	atgacttggc	tggatgatct	14640
tgggcaagtt	gtttaacctt	ttcaggtctt	gtttcttcat	ctgtaaaatg	gagctaataa	14700
taatattgcc	catcacatta	ggttgttgta	agaattaagt	gaggtagtaa	attagaataa	14760
tgtggtacat	cagtatatta	atacatgaga	taataaatat	atgaacgtga	cgtggctttc	14820
cacagagtga	atacatgctt	agctagtgat	tgttagccat	gcatctgagt	tgggggagac	14880
ccagccagtg	ggtgactctc	tgatcaggtg	tcactcagtg	ctacaggttc	ccggccagtg	14940
tacctgtagt	aaaagggcag	cggtggcatc	catacctctt	aatccaaggc	agctttggcc	15000
tcagtgcctg	tgcagtctcc	tgactggcca	actaggctgg	gccacttgtc	aatggggtgg	15060
attcgttttt	ttgtttggtt	ttcagctccg	agttcaaaag	cctgggagac	ctgctggctt	15120
ctctcccaga	cctgggcccc	atattgttaa	cctgggccct	ggaggtctga	tcagtgtcct	15180
ggctggatcc	agtgcagtaa	gagaagccaa	ggagaagaca	gtcttccaag	gcctgaagca	15240
ggtctgacct	aactgcccaa	tgtaggaggt	ttgccctggg	acaaactaag	gtcctgcagg	15300
gttcgagggt	gaaaggcctc	ttctcccagg	aggcagcccc	agacccacct	tgctgaactg	15360
gctgcctgga	aaggaagtga	gagcgaagat	ctcaaaaaag	agcagctctt	taacctctgt	15420
gctgctctca	ctgaacgctc	ccgccctctg	cccaggactt	gatggctttg	gccctggccc	15480
tggggcagag	cgaagggaaa	gcgtcagtgc	cctctagggc	cgagagtgtg	gcactacagc	15540
aagtgtgtgg	tgggtgcggc	tgacttgtgc	tctgtggcta	ctacccatcc	ccatcagaaa	15600
cctgggcctg	tttccttctc	tggaatggtg	ctgggacttt	ccaaaccacg	gacctgtagt	15660
gatgagagtt	ggtgtcttga	gtccgcgtcc	accgtctgca	tgccatgcct	gccttcccac	15720
tgctgggggc	cctcaaccct	cctccagttc	ccgtgtctaa	gacttagcaa	caagcatcct	15780
tcctgtgtgt	tggactgcgg	gtctgcacca	ttgtgagaca	cggtcctata	ttgggcccta	15840
cctctatcgg	tgctcgttga	cctgactggt	atcacagtcc	tcatctggaa	cggggccagc	15900
caagetetgg	ccactccctt	gtcctgggac	gaaggctcag	cccctgaggc	ccggcgagta	15960
gtcaaggctg	gctctctgat	gcctggctgc	tctgatgctg	gcatcctgca	tgcacttcca	16020
gctccagcct	tgtcctgctc	aaattacccc	tcattattga	tctggtccat	ctgttgagtc	16080
accctccagt	ttttttcttc	cactttgttt	aatgcctggc	actcaaaaga	cagccagtag	16140
					tagaatctgt	
tgttttcata	cctccttcac	ttgttaagat	tttcatctcc	tgccctgact	tcagtgggta	16260
					aggtgattgg	
					gcctgggtga	
cagcctcact	gtgtgttggc	aggcttctca	ctcacctttt	ttaatcaatt	ggacctgaaa	16440
atcttgaagc	taaacaaaca	cagccctgct	attttggcac	aagatgaagg	ccagttttaa	16500
gtggtctata	aaagctgtga	aaaaaacttt	taaaagagaa	ttatatccag	ggcacccaag	16560
					aatcccttta	
					aaggacttcc	
					tcctgtagcc	
					atttaaaaat	
					tttcctgaat	
					ctggaaccac	
					actcttgagt	
cacatctttg	cacacccaga	agctccaggc	ccaccgtgta	ccatggctaa	gtagctgcaa	17040

ctgcaacctg	gccttggcct	ggaagcacat	cttgtaggat	cactgatgtt	actctcccct	17100
ggccttcccc	ttgtcctgga	agatgtgcct	aaggctgaga	gacttcattg	tttaattcat	17160
ctagctgtct	gttctgagag	ccccagcta	aactgaggtt	ccagtcccag	aacagctagc	17220
aaaccgccct	aaggggaaat	gaagggaga	tggacatggt	atttactgcg	tgcctttcat	17280
aggatgctgc	ttttacctgg	tagatggccc	aatgcctagt	tgtctgacct	gtgaccaggg	17340
geteetegee	tgggaaactt	gtttatatgt	ctttgtggct	cttgcctttc	ctgtgttcag	17400
tttatgcccc	cctgcccatt	gctctggcgc	tgggagccaa	accttgtgct	ctcttgggca	17460
tcccaaggta	aaacctggcc	tggggcattc	cctggtcttc	agatggaagg	tgcaaaggca	17520
atatacacca	cagtaggaaa	caaattcaaa	aagtgtaatt	tacggatcct	gggcagggag	17580
ggcacagaga	gtcgggaggg	cagtcctttg	tccctgggcc	actccagata	ggaatgaagc	17640
atcatgcaga	gagagagaaa	caaggcacat	ggcaactggc	agtgtgtata	gggagtaggg	17700
tctgggccac	tgtaagtttt	caggcaaatg	tgtgaatggc	ctgtttaaag	gaagcaatgg	17760
ggaagcaggg	agcccagtct	gctagtcagg	ggagatgtct	ctaagttttt	atctctcgcc	17820
actggcttga	gccattgggt	gtggtttcct	tctaatgcct	gggcagctgt	gtcattcccg	17880
					ggcagcccaa	
caagtgggct	cctctggcca	gtgagggagc	ctggtgaggg	aatcttccca	ggacaggcag	18000
					ggatatattt	
					gctcaaataa	
	_				tttttttt	
			_		gagaatagaa	
					cagetggaaa	
	_	_	_		aaactagatt	
					agtttttcc	
_					tggcacccaa	
_		_	-	-	gcataattaa	
					gaattttgct	
		_			ataaccccta	
_				_	tataccacga	
					ggaactggaa	
					gcactgattc	
agaacagcag	gggctggctc	tgtactgggt	gggtgggtgc	tcaaggccag	acctacacag	18900
					ccaggagagg	
					ggagcatcaa	
					gatttagatc	
					gatgcctatc	
					tatgcagagc	
					caaaggtggg	
				_	gccctgattg	
					ctgtgtgctt	
					gggacaaaaa	
					gttacagaag	
					aggtctgatt	
					tctgggaaag	
					tgtccgattg	
				-	tctgtgggtc	
					tttgatgtgc	
					gaagtcatgg	
				_		
cyactygaag	Lautytataa	cccyacaya	yycasa	LLLLayetga	agggacctcc	エンスペロ

agggagaagg	gggttgggga	ggggagcagt	tggctggggc	ttcttggccg	cctccattgc	19980
cctttggttc	agecagecea	ggctcacagc	agatatcctt	gacctcgcca	agggaaggct	20040
ctgaaagaca	aaggtagatc	ttgatcttgc	ttaactgtgc	acttgagctt	gcagttcctt	20100
gaaagatctg	gtgtcacgca	agacaaatta	tacagcagtc	tactatttct	ggagtttgat	20160
cattctcagc	actggcttta	tttcttttt	tccactaaag	aagtatagtt	caaatgtgga	20220
taggtgaaag	tagataatct	taggaggatc	gttacaaact	gaaatgtcca	tgagttcagg	20280
aaagtgccat	gtgtgtgagg	ggtaccccag	gtgagaggcc	tgaggattgg	gcaggtgaaa	20340
gggaccatgt	gggcacagga	ttcatcccc	tcaccatgtg	ctttctcact	ttagtgatga	20400
tttctaccca	ggtgttgact	aagtcactta	ttgacatgag	atcagaagaa	acaagttcaa	20460
gttcaacaat	ctccgcatgg	gatcttagaa	ctctgaaact	ctgtgacctt	cacaaggtta	20520
cctctgggtc	tagattttt	aactggaaat	caaggacaat	cattaagaga	ctcccttcc	20580
tggattgttg	ggaagattaa	atgatacaat	ccaagtaatg	agagcattgt	agtctctaaa	20640
attggattct	caaataatga	cctcaggtga	aggaagaact	gttcaaaatg	ccccaggtgc	20700
tatgaagtac	agagggcagg	tattttttt	aagggatggg	gtcttgctct	gttgctcagg	20760
ctacagtgca	gtggtatgat	catgactcac	tgccacctca	agctcctcgg	ctcaagtgat	20820
cttctcacct	cagcctccca	agtagctagg	actaaaggtg	cataccacca	tgcctggcta	20880
atttttaat	ttttttgtag	agatgggggt	cttgctatgt	tgcccaggct	ggtctccaac	20940
tcctcaagca	accttcccat	cttggcttgc	caaagtgctg	ggcttacagg	tatgagccac	21000
	_				gaacagagtg	
					taaattttgt	
					gacagaaaat	
ggcaaattct	agctgaattt	taaattgtgt	tatttgcgga	ataaaatatg	tggacaagtg	21240
					aggcgggcac	
					cttggcattt	
					gactttcttc	
					ttcagcagtc	
					tctgaggtca	
_					ttgggtcttg	
					ttcactttta	
					aggctttaat	
					gtgggttgca	
					tgtatatata	
-					aggacatggc	
•					tcccactttt	
					ataagcacag	
					cccaacgcag	
					ttgaggttct	
					tgttcaggat	
					tgaagctcat	
					tccaacccat	
					tagtctcacc	
					gggactctta	
					tetteteete	
					attttatggt	
					ttgcttaaaa	
					tctttatcca	
					tttcagaatg	
cctttaaggt	gggaaaacat	tttgtatcat	tttcaacatt	tgtatcagtt	tgaaatctgc	22800

ctgctaagta	acaataaaaa	agttagcaac	ataatttatg	tttaaaagga	agtgttctgg	22860
ggtgatgttc	gagttggaaa	cttgccctat	gctttactgc	attgtgatct	tcagcaagat	22920
attttagttc	tccagatttc	cgctttccca	gctgtaaaag	gagacaacaa	tatgaatttc	22980
agtgaacata	aaaagcaccc	attatttat	acattgcaaa	gaaagaaaaa	ttgctgtcaa	23040
ttaagcagta	acagtgcttt	ctatggttta	gaatttttat	cttatactta	actgatatag	23100
ctcttttaga	tgtatttagg	cttttgaaaa	atcacatatc	actcattaaa	aaggaaaata	23160
aattggttaa	ggttttcctt	ggcatcttct	tcttcattct	gagtcttccg	aaacacattt	23220
ggactcaatg	ttgtcgaggt	ttgtgtttcc	ccacacgtca	tcatcctgtg	aaccattgaa	23280
gttgatggga	ggcaactttt	tctcccccaa	gaataaagag	ttttctgtag	gattgtctgc	23340
caaactgcta	acacctttct	tcaagttttg	aatgctggtg	ctttcccagt	cttacaaatc	23400
cacatcaaca	caagattttc	aggcaacagc	cagtacgcag	atggtcctaa	aatagtttgt	23460
acattgaaac	accagggggt	tgcagatggt	cagccaggcc	agggaaaata	atccagttat	23520
aaccactgca	tcctgaccac	ttcctggctg	atggtgattg	taggacacat	ccctgtttca	23580
gagatgttaa	aatgtaaaat	aataataata	ataataataa	taataataat	aataatataa	23640
gatataacct	gtttcctaaa	gttgtgatga	catttaaagg	tgagaaagtt	tgtagctatt	23700
attgtgatta	tggttactat	aaattctgag	aaaacacagt	ggggttttct	aattaacact	23760
aactaattta	tgggacactc	attaatgtta	tatatttatt	tattgttcaa	tgttcatgct	23820
taaaaatttc	ttaatttttc	ctctttttaa	ttgaggtatg	gtttatattc	agtggaatgc	23880
acaggtctta	agtgtttaca	gttcttgaat	tttgacacct	gtgttacgaa	cagccctacc	23940
aagagataga	acagteteat	cactcaagaa	acaacaccct	atcttgtccc	agtcatcatc	24000
gtccctcctc	tgttctgata	tcttctacca	tggattaatt	ttggctgttc	tagaacttaa	24060
tggaatcatg	tggcactact	cttttgcatc	ttttctaaag	acatgtacat	gttggctggg	24120
cgcggtggct	cacgcctgta	atcccagcac	tttggaaggc	tgaggtgggt	ggatcacrag	24180
gtcaggagtt	tgagaacagt	ctggccaaca	tggtgaaacc	ccggctctac	taaaaaatac	24240
aaaaattaac	tgggcgtggt	ggtgggcact	tgtaatccta	gctacttggg	aggctgaggc	24300
aggagaatag	tttcaaactg	gaaggtggag	gttgcagtga	gctgagatcg	taccactgca	24360
ctccagcctg	ggcaacaaga	acaaaactct	gtctcaaaaa	222222222	gaaagaaaga	24420
_	tacatgttgc					
	catagctata					
-	tggggctggc			-		
_	tgacatgttt					
	aggtatacat					
	tgcgtgagag					
	tttgaaacat					
	atgattaatg					
-	taaaatgcct	-	-			
•	aagttgtagt			_	_	
	tgacttgtcg				_	
-	gcccatttat			-		
_	caaagtcaat					
	gtaggcctgt	_				
	aatattttt			_		
	ttcctcattg					
	ctgtttattc	_		_	_	
_	tttatagtgg	_		•		
	gtcatcctcc					
	gtcttctcct					
ttettette	tecetetect	tetttgaggt	ggggacttgc	tatgttgccc	agacaagagt	25680

gtagtgcctg ttcaaaagtg caatcatagt gcactacagc ctcaaactca tgggctcatt 25740 cttctagatt ttatttgttt agatatgaag tctcactctg ttgctcaagc tggagtgcag 25800 tggcaggatc tcagctcgct gcaacctaca cctcctgggt ttaagtgatt ctcctgcctc 25860 agcctcttga gtagctggga ttacaggtgc ttaccactgt gccagattaa tttttatatt 25920 tttagtaaag atagggtttc gccatgttgg ccaggctggt cttgaacacc tgacctcaag 25980 ggacceacea ceteggeete ecaaaatget gggattacag gtgtgageea cecatgeeca 26040 gctcactttt agacgtttta gaataagcac ataaatttct acaaaagaac ctcataacat 26100 tttgattgga attatattaa atcaatgaat caatgtgggg aaaattgaaa tcttaccaat 26160 attgaacttc cagtgtatgt atacagtgta tcttttaaat tatttgtctt taatttgttt 26220 cagcagtttt ggaaaaatag ttttcactgt agagctctgg cacatattta aagaaagtat 26280 ccctcagtat tatgagattt aaaatatttt gtaaattgta ttttttaaaa aatcatcttc 26340 tagttttttg ttatttagac ataagattga tgtttgtaca ttgaccttgt atcctgcaat 26400 cttgctacat ttaatttatc atatattttt ctcagtgctt tacagaattt cttgtttatt 26460 cttgtaacta cctatgagtc aggtgttatt gcaattatat tttataagaa atttgcccca 26520 gatgtgctaa ttttcttgct ccaggtcaca caatttgagt aacaggggag gaatttaatt 26580 taggteaact ctgattatat ggcccagtec ccttecacac tgctataata tgtcatctct 26640 ttgacatttg tatattattg gaatggagtg acacattgtg gtttctctgg attccactgg 26700 gacatttttg ggtcatcata ctttacggga gatggcttca ccaatggaac tcctaaaatg 26760 gacataacaa gaataaggtg ataaaaaaga cggtgatttt tccagtttaa ggggagcaat 26820 atttttccag gttctttccc cagaggactg ctaaggaaat tgwacataat ctcaaagtgc 26880 agtttetttg eccatgetgt gaatgtacat tagetgetge tagatettee atgtgtgtgg 26940 atgctgtama gcttgttttc ccttcttctc tcccacaacg tgctgtagga aaccatttct 27000 ggacggctaa agacctcacc gaggagatta gatcattaac atcagagaga gaagggctgg 27060 agggactect cagcaagetg ttggtgttga gttecaggaa tgteaaaaag etgggaagtg 27120 ttaaagaaga ttacaacaga ctgagaagag aagtggagca ccaggagact gcctatggta 27180 ggtagtgcac aactgttacc ceggeaagat attgatgata tttgttgtgt tttgtggeca 27240 ggcagaatgt tetgtgeett watgtgaaeg tteaetgtga agagegteat ggageaeatg 27300 gecettttee ettggggaca tttttggeag gtgeettgge aaactgaatg gaatwacttg 27360 teagettttg ttttcatatt cacatgwgae atettttett tttetgttee etgteteaac 27420 ctgtgtttgc taatageett gttattattt agageagtet etceettgge aaggtettga 27480 geattitett tgigigacaa tiatetteet titgieeett ggeteegtet eetigistge 27540 acaatcatag actaaatcag gotgatotga gaaaattgag ggaagaccat aaaqtqqoto 27600 ttctatgtgt ggacttttct gagagcttct ttccccagga aggatgatgt agaagatgtq 27660 aatgccgcct tagccaaagt gtctgcttgt cagaggagtt caagtgttcc tgtgttcttt 27720 ccttttccag tcgttaggag taactgagct tactctgaga tttgcaccca gagggatggt 27780 ctcagaagac gctggttcag tgcaaattga gatggtaaaa acttatttct taaaaaatgg 27840 ttcctaaata aatgtcattt actaaaacaa atgaaagaaa tatatatatg aataaatggc 27900 tatattttac aaagtatgct tatttaagaa gaaataagaa aaaacggggc tgataggaac 27960 cagatttgaa atagggettt tgtaaatact eegtaaattg aagtaaatga agagtagtat 28020 ttataagota gattgagaaa tataaaatca gotagotgaa gttaagtgoa toaatttggg 28080 atgaataaat tttettttaa aatgtetate aatttgtgta gagagaggtt tetteataga 28140 gatattagaa tcaaagagta tgttcagtag ttattctgtc ttctttgtaa tgaataccct 28200 taagttggct taacagctca gtacttatct ttttttcttt tcattcttaa aggtcaagcc 28260 ttgtttttgc catatatgta actagagaca gtacgtttga ggctaaataa ctgtagtact 28320 agggaatgac aacacgetea eecaagacae egcageetgg tttactetgt catgatagga 28380 atgaggattg tacatttgaa ataggtttct gctattgatt ttttaaatgt ataaacgatg 28440 gaaactacgg aattteteat gtttteacea catagttttt tgteataaaa tgaagaatat 28500 attatateca agaatgaaga ggaagtgaac aaatttgage aaatttagte cagcaatatt 28560

					aagaaccatg	
					atgaataaaa	
					gatggctcat	
					cagccaccct	
					gtgagttggc	
					aaataatgaa	
					caaagtccat	
					gttcaagttt	
					catgcatgta	
					tatgtagtat	
					aggggaaaaa	
					tctatcttgt	
					ccacatgcat	
					ccctttaagt	
					cttaaccttg	
					gggcagcaat	
					gcagtcttag	
					gtatctctaa	
					atcttgtgtc	
					actgtactgc	
					aatatttgtt	
					ctgcatttta	
					ttaatgaggg	
					tattcagttt	
					ccaaggtact	
					ccaagacaca	
					tcttgagact	
tcaggataac	acatttgaat	tcggagcaat	gttaagtgca	gtgaaataga	atgaaaagct	30240
					taattattgt	
					gcaactttta	
					cttcttgcaa	
					ccaggttcaa	
				-	atttttatat	
					tcctgacctc	
					gccaccgcgc	
					agcagttttt	
					tgttgatttc	
					tcacagaata	
					cccaccttat	
					ctggttccat	
					aagggattct	
					actgtgccca	
					aaggggcagt	
					attaggacct	
					aattcttggc	
					tgtcttagtc	
					aagggaattc	
cttggctcac	agttttgcag	gctgtctaag	aagcatagtg	ccaacatctg	cttctggtga	31440

```
qqqcctcagg ctgcttccac tcatggcaga agatgaaggg gagctggcct aggcagatca 31500
ctggtgagag aggaagcaaa aagagagaga agggacatga cacactettt ttaacaacca 31560
gctctcccag aaactattag agtgagaact cactcattga tgaccaagct attcttgagg 31620
gatctgcccc cagacccaga cacctcccat taggctctac cttcaacatt gggggtcaaa 31680
tttcaacata aggtttggag gtcaaagaaa agaaactata gcagtgacag attatactga 31740
gatateggtt taactetgaa gtteecagat geagetactt geagaattte actteacace 31800
tattaagaaa agtottttag tttagaaato otgtgagtta caagttotgo atatataggo 31860
aqtaattett ttttecatat atgteagata tatgtagaag aaacattgat gaaaaagtag 31920
aacaaaaqaa taaaatctat gggtctcttt tattggcagg gagagggagg aaatggagag 31980
ccqqqacaat acatacaaca aagataaaaa caataaaatt agcaaacaac aataaaattt 32040
aaaaacaaag acagaagaaa atgccaatgt caagtgttaa ttatttggtt gagaatatga 32100
tgtgataatg aactteetag aagteacage aaagaagaca gttgaageat cateettett 32160
cctcaaaagc accttgaaaa gcacagagct ttttgggaat tcagagtgat gctaaattct 32220
tcaagacact tctcttgaaa gcatagtgga aagtcctcct gaacagattt ataacacatg 32280
cagaaagete ttttacttgt attattattt tttacaactt tttattttag gttcaggaat 32340
acatgtgcag gttctttata taggtaaatt gcatgtcatc ggggtttggt gtccagaata 32400
ttttatcacc caggtgataa gcatgttatc cgatggttgt gaccaactac ctctaggaaa 32460
aaaacatgtt ggggatccct tcaaagcagg agggactgtg cacaggagag actgaaacca 32520
catacacatt ttagatatgt aggtatggac agtttttccc acaaaaagat ccagtttttc 32580
agcagatttt taaaggggtc attctaagag tcctcaaatt ttaagaaaca ttaagatatt 32640
aaactgtega ggtgaattag ggettggget agtgaagttt aaatacggea tettecaatt 32700
tctgacatta tttcaagatg taacttagca cctaaaaagt ggctggagaa catatcctgt 32760
acactcacca aatgtcactt ctttcctctg agctttggct acgacctatg tataagaaaa 32820
cttagctctc cgggccagaa cggtgatagt gctcttgata acagagggcc aagccgtctg 32880
ctttggaacc agatgagtgt tgcggtgcta tgtggcaaga aatgtagatg tttatatggg 32940
aaataqatat gtgtctgcct ttccaaattc gaaatctttg gtcatttaga tttaaaaaaa 33000
tatgtcaaat aggatetttt ggaagaaata aaaaaaatte aaaatetttt eecteaggtt 33060
tttctgatag gctgaagttt taaatctcta atcatttatc tttgatttgc cttattgatt 33120
acattateae tttateagga ecetgaetaa atetgtttgt gtttttaatt teteteeatt 33180
ttttcctttc cagttacatc cttgcatcac tattagtgtg attatttccc ttcagccatt 33240
tttgcctgtg aatttctaag cttgaaattt gcaactaact ttctccctcc tttattaagt 33300
cgctgtgata attettttgg gaggcatege catacagtgg aaaaageetg gattaggatg 33360
tagggggtgt cagtttaatc tcagtcctgc ccttccctaa tcatctgcat agcacctgat 33420
atatatagca tcagaatgtg aggctcaatg agtgaatagt cttcagcaac tcactgaatt 33480
ttatctgagt ctcagttgct tcatatgtaa tactgtagaa ccagatcttg aagttgcatt 33540
totatocato catocagoca tocatocato catocatoca cocacocato catoctttoc 33600
acaagcattt attgagtact tacgatatgc taggcgctgt ggcaggccct catggtccag 33660
agatgaatta gatagtccct gtggctactg aggtcccttt taactctagc cccttgtatg 33720
tgaatttcca caattcaatt tatactttgt tcatttattt tcttgctctc agctactttt 33780
```

```
<210> 5
<211> 28
<212> DNA
```

<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:synthetic

oligonucleotide

<400> 5

ggctggatat tgcccttgag ccataatt

28

<210> 6

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:synthetic oligonucleotide

<400> 6

agaacagagg agggacgatg atgac

25